


















A thesis submitted for the degree of Master of Health Sciences, 


















Tuberculosis (TB) disproportionately affects migrants to New Zealand. In 2016, 79% of all 
cases were in those born overseas. The World Health Organization (WHO) has called for 
low-TB incidence countries such as New Zealand to aim for TB elimination. A focus on 
reducing TB in risk groups, including migrants, is necessary to achieve this. Despite 
radiological screening, TB still occurs in migrants, and little is known about specific risk 
factors for TB in migrants to this country.  
This study aims to reduce the impact of TB in migrants to New Zealand by identifying risk 
factors and auditing current TB immigration screening procedures.  
Objectives 
1) To calculate TB incidence in migrants according to nationality, region, visa type, age and 
sex. 
2) To assess if TB was identified at the time of immigration screening, and if not could it 
have been.   
Methods 
Cohort study: TB cases were linked to the Statistics New Zealand Integrated Data 
Infrastructure (IDI) migration records from 01/01/2007 to 31/12/2016. All long-term 
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migrants to New Zealand were included in the study. Border movements for arrivals and 
departures were used to calculate total time in New Zealand per migrant. TB rates per 
100,000 person-years were calculated for nationality, region of origin, visa category, age and 
sex. Multivariate analysis of incidence rate ratios was calculated for region of origin and 
WHO incidence in country of origin adjusting for visa type, age and sex. 
Clinical audit: TB cases were linked to the Immigration New Zealand (INZ) health screening 
records from 01/02/2015 to 31/01/2018. Screening records, x-ray reports and specialist letters 
for TB cases were audited to identify whether TB was diagnosed by screening, and in cases 
where it was not diagnosed, possible gaps in the screening programme.  
Results  
Cohort Study: There were 873 TB cases in 1,597,077 migrants, with a total of 2,851,287 
person-years of follow up. The highest incidence of TB was seen in those from South-Central 
Asia, with 104.8 cases per 100,000 person-years (95% CI: 95.7- 114.9), followed by South-
East Asia with an incidence of 59.2 per 100,000 (95% CI: 51.9-67.5). Incidence by country 
was positively associated with incidence in the country of origin, but incidence was less in 
New Zealand than in the country of origin. Incidence in New Zealand was proportionate to 
WHO estimated incidence, with the exception of migrants from the highest WHO incidence 
bracket ³350 per 100,000, where New Zealand incidence reduced. Migrants from countries 
with a WHO incidence of <40 per 100,000 had a New Zealand incidence of 2.8 per 100,000 
(95% CI: 2.0-4.0). On multivariate analysis, region of origin and WHO estimated incidence 
were strongly associated with TB risk in New Zealand. Age <15 was associated with a 
reduced risk. Visa category was not associated with risk of TB once other factors were 
adjusted for.  
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Clinical Audit: There were 120 cases of TB included for audit. Immigration screening 
detected TB, or was likely to have detected TB in 46 (38%) cases. In 74 (62%) cases, 
screening did not detect TB. In those not detected by screening, 13 (18%) were notified 
within six months of screening, and thus were likely cases of prevalent, active TB. Six of 
these cases were pulmonary TB, and five of these either had old, or no x-ray submitted as 
part of their immigration medical. Seven were cases of extrapulmonary TB. There were 50 
(68% of those not detected by screening) cases of likely reactivation of latent TB (LTBI). 
The remaining cases not detected by screening were likely due to inactive or early TB (8 
cases) or possibly infection in New Zealand (3 cases).  
Conclusion 
This study is the first to describe risk factors for a large cohort of migrants to New Zealand 
and is the first audit of the country’s screening programme. The cohort study identified the 
main risk factors for TB in migrants are the world region and TB incidence in the country of 
origin. The clinical audit showed that there is limited scope to improve on currently used x-
ray screening of migrants, with most TB not detected by screening being due to reactivation 
of LTBI.   
This study has identified high-risk migrant groups that could benefit from enhanced TB 
screening. Overall findings support the idea that LTBI is the cause of most TB in migrants in 
New Zealand. Further study is needed to assess possible benefits and costs with additional 
screening, such as for LTBI in high risk groups. There is a low incidence of TB in New 
Zealand in migrants from low WHO incidence countries, and consideration should be given 
to abandoning screening in these groups. A change in screening procedures will reduce the 
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incidence of TB in New Zealand and its considerable impact on migrant communities, and 
help progress New Zealand towards TB elimination.  
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Chapter 1: Introduction 
Overview 
Tuberculosis (TB) is a communicable bacterial disease caused by Mycobacterium 
tuberculosis complex. Globally, the greatest burden of TB is seen in low and lower-middle 
income countries, where incidence is driven by social, political and economic factors (1). In 
high income countries, such as New Zealand, TB disproportionately affects migrants and 
those living in poverty (2). TB usually progresses from a latent, non-infectious state (latent 
TB – LTBI) through to active TB disease (3). Limited TB screening of migrants, in the form 
of chest x-ray and medical examination, is undertaken in New Zealand, but LTBI is not 
routinely screened for.  
Global tuberculosis epidemiology and control 
Failed global control means that TB remains a public health threat in all countries, including 
New Zealand. In 2016 there were an estimated 10.4 million new cases of TB, with 1.7 
million deaths globally, making TB the leading cause of mortality from a single infectious 
disease (1). The burden of TB is concentrated in certain parts of the world, with over half of 
all global TB cases occurring in five countries: China, India, Indonesia, Philippines and 
Pakistan. Eighty-seven percent of all cases originated in thirty World Health Organization 
(WHO) designated high-burden countries, with the majority of these being low and lower-
middle income countries in Africa and Asia. Incidence in these countries ranges from 42 
cases per 100,000 people per year in Brazil, to 781 per 100,000 in South Africa. In contrast, 
in most high-income countries the incidence is <10 per 100,000. Mortality varies from less 
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than 5% of cases in some high-income countries, to over 25% in many African nations due to 
underlying malnutrition, human immunodeficiency virus (HIV) coinfection, access to 
treatment and quality of treatment (1). 
The WHO adopted the End TB Strategy in 2014 - an ambitious set of targets with the aim of 
‘ending the global tuberculosis epidemic’. This strategy calls for a reduction in the global 
incidence of TB of 90% by 2035, which would result in a rate of less than 10 per 100,000 
worldwide (4). Progress in reducing the incidence of TB is painfully slow at 2% per year, 
whereas an annual reduction of 4-5% is required to reach the initial 2020 End TB Strategy 
target (1). Globally, TB control focuses predominantly on active case finding and treatment. 
Contact tracing and prevention measures, such as infection control, preventive treatment for 
M. tuberculosis infection, and vaccination are implemented to varying degrees dependent on 
country-specific TB incidence, health policy and funding (1).  
Global control is hampered by multi-drug resistant TB (MDR-TB), HIV associated TB, 
poverty, diabetes and undernourishment (1,5). Undernourishment is seen in 1.9 million cases. 
HIV is estimated to contribute to 1.0 million cases, and the majority of people with TB are 
co-infected with HIV in some Southern African countries. MDR-TB is seen in 4% and 19% 
of new and previously treated cases, respectively. Close to half a million MDR-TB cases 
developed in 2016, with 47% of these originating in three countries: China, India and Russia. 
MDR-TB is a major public health concern, due to high health system costs, treatment 
complexity and lower cure rates (1). 
Low TB incidence countries, defined as those with an incidence of <10 per 100,000, will 
need to reduce TB incidence further to achieve pre-elimination (<1 per 100,000) and 
ultimately elimination (<0.1 per 100,000) levels (6). TB risk in low incidence countries may 
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be concentrated in vulnerable or hard to reach groups, such as recent migrants, the homeless, 
those living in institutions or living in poverty (2,6). In many low incidence countries, TB 
rates in the non-foreign-born population are very low, with a much higher proportion of cases 
occurring in migrants than their proportion of the population. TB in foreign-born persons can 
make up over 80% of nationwide cases in some low incidence countries (7,8). In many 
countries, migrants are screened for TB before, during, or after entry to their host country, in 
an effort to reduce incidence and transmission (9). Despite these measures, annual incidence 
rates are not decreasing fast enough to reach elimination in the near future. Improved and 
sustained interventions, such as focusing control on risk groups, including migrants, are 
required to meet elimination goals in low incidence countries (6).  
Tuberculosis in New Zealand  
Information on TB in New Zealand comes from annual reports summarising the 
characteristics of notified cases (2). In 2016 there were 294 cases of TB notified in New 
Zealand, at an incidence of 6.3 per 100,000. This rate has been constant over the preceding 
nine years. Overseas birth is the dominant risk for TB identified in New Zealand cases, 
present in 79% of TB notifications in this country. This proportion has been stable for the last 
seven years. Notifications occurred after one year of arrival in 17%, and within five years of 
arrival in 49% of cases. Incidence is calculated using census estimates and is not linked at an 
individual level. The highest incidence of TB is seen in those born in the South Asia, South 
East and Central Asia, followed by Sub-Saharan Africa. Those born in the Pacific Islands, a 
region with cultural ties and high immigration rates to New Zealand, had an incidence eleven 
times higher than those born in New Zealand. Incidence in Māori was three times higher than 
those of New Zealand European or Other ethnicity. TB in New Zealand is linked to poverty, 
 4 
with a disproportionate number of both foreign and non-foreign-born cases residing in 
socioeconomically deprived areas. Similar disparities are seen with all infectious diseases in 
New Zealand (10). Mortality is low, whereas morbidity and personal costs, in terms of time 
off work and periods of isolation are high. Costs to the public health system from contact 
tracing and treatment, drug administration and monitoring are also considerable.  
MDR-TB is uncommon in New Zealand, with only four cases reported in 2016. In the last ten 
years, 29/31 (94%) MDR cases have been in foreign-born patients (2). MDR-TB is a 
significant public health problem, due to the need for prolonged isolation, treatment 
complexity, drug toxicity and the lack of an evidence base for preventive treatment of 
contacts (11). Treatment costs for MDR-TB are significantly greater than those for drug 
susceptible TB, being five to ten times higher in European countries (12). In New Zealand, 
one case of MDR-TB treated in Wellington was estimated to cost over $320,000 (13). With 
large numbers of migrants arriving from countries with high rates of MDR-TB (1,14) the cost 
and potential public health risk in New Zealand is considerable.  
A quarter of New Zealand’s population is made up of migrants, one of the highest 
proportionally in the Organisation for Economic Cooperation and Development (OECD) 
(15). The top source countries for permanent migration include three high-burden TB 
countries: China, India and Philippines (14). New Zealand has a TB screening programme for 
incoming migrants, which is designed to detect active, pulmonary TB. There is no current 
screening for LTBI, with the exception of quota refugees under 16 years old.  
Improved control of TB in New Zealand requires further understanding of the risk factors for 
developing TB in migrants, and evaluation of current screening practices. To date there has 
not been a detailed analysis of risk factors for TB in the migrant population, information that 
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would be essential for improved preventive efforts. Likewise, entry screening for TB has not 
been subject to formal evaluation by linking health and immigration data. This thesis will 
study risk factors for TB in migrants to New Zealand and will audit recent immigration-
related TB cases to identify opportunities for early diagnosis or prevention. 
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Chapter 2: Background - tuberculosis and migration 
Tuberculosis natural history, diagnosis and management 
Tuberculosis natural history 
TB is a bacterial illness caused by Mycobacterium tuberculosis. It most commonly affects the 
lungs (pulmonary TB), where it is potentially transmissible via droplet spread. Extra-
pulmonary TB may affect any part of the body, but commonly causes disease in the pleura, 
lymph nodes, bones and joints, gastrointestinal and central nervous systems (3).  
The natural history of TB has been comprehensively described (3). Infection is usually 
followed by a period of latency, and then progression to disease. Infection depends on 
multiple factors including source case infectivity, proximity and length of contact with the 
source case and the susceptibility of the contact. In practice, infection with M. tuberculosis is 
inferred from likely exposure and a positive immunological test (tuberculin skin test – TST, 
or interferon gamma release assay - IGRA) (16). Most people infected with M. tuberculosis 
do not progress to develop disease. The consequences of infection in any individual depends 
on the balance between bacillary multiplication and immune containment. In approximately 
90% of infections, no disease is clinically apparent. Incompletely understood immunological 
factors contain bacterial spread, resulting in non-replicating, but viable bacteria residing 
intracellularly. This dormant state of infection is known at latent TB (LTBI). Patients with 
LTBI are asymptomatic and non-infectious. 
Those infected with M. tuberculosis may develop TB. Approximately 10% of infected people 
will progress to TB disease in their lifetime (3). This may be primary, or post-primary TB. 
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Primary TB occurs when there is no latent phase of infection. Immune responses are unable 
to contain the initial infection, which progresses, resulting in pulmonary or disseminated 
disease. This often occurs over the period of a few months. Young children and 
immunocompromised (in particular HIV infected) patients often present with primary TB. 
The more common form of TB disease is post-primary TB, caused by progression of LTBI. 
Latent TB may affect just under one quarter of the world’s population (17). After a variable 
period of latency, dormant but viable bacilli reactivate and lead to disease. Currently there is 
no reliable way to predict which patients with LTBI will develop TB. The likelihood of 
progression is influenced by immunosuppression. Reinfection can also influence progression 
from LTBI to TB.  
Clinical features 
It is likely that an individual passes through a variety of clinical states as latent TB progresses 
to clinically apparent TB (18). Slow progression of symptoms is common, and patients are 
often unwell for some time before a diagnosis is made. Pulmonary TB is characterised by a 
productive cough, lung infiltrates and sometimes cavities on chest radiography (3). In 
pulmonary and extrapulmonary TB, the latter stages are usually characterised by systemic 
symptoms such as fevers, night sweats, weight loss and malaise.  
The diagnosis of TB is confirmed by microbiological evidence, from either microscopy, 
culture or molecular techniques (19). Sputum is sampled in suspected pulmonary TB. In 
suspected extra-pulmonary TB, samples are taken where feasible (e.g. biopsy, aspiration of 
body fluids). Microscopy, culture and molecular techniques are performed to identify disease, 
and in the case of pulmonary TB to indicate infectivity. The amount of bacilli detected on 
sputum smear is positively associated with risk of transmission to contacts (19). Culture and 
 8 
some molecular methods confirm the diagnosis and allow identification of drug resistant 
strains of TB, and thus are employed whenever possible to direct treatment. Chest x-ray 
findings may support a diagnosis of pulmonary TB, but in all cases laboratory diagnosis is 
required to confirm disease. This is not always possible, especially with children who usually 
do not expectorate sputum (20), and those with extra-pulmonary TB. Whilst not ideal in the 
era of MDR-TB, a probable diagnosis may be made based on exposure, immunological tests, 
clinical findings and response to tuberculosis treatment.  
Tuberculosis management  
Standard TB treatment consists of four medications taken for six months (1). Longer courses 
are required for some forms of extra-pulmonary and meningeal TB, and for drug resistant 
cases. Globally, treatment is successful in 83% of cases. In New Zealand, treatment 
completion ‘to the satisfaction of the prescribing doctor’ is seen in 85% of cases (2). For 
MDR-TB and extensively drug-resistant TB (XDR-TB), global treatment success rates 
(defined as cured or treatment completed) are 54% and 30% respectively. Morbidity from TB 
is high, and patient costs, from lost income and out of pocket health expenses, are significant 
in both high and low income nations (1,21). Directly observed treatment (DOT) has been a 
mainstay in ensuring treatment adherence, although is not always employed in New Zealand 
(2). Adherence to treatment is crucial to prevent emerging drug resistance.  
Active case finding, contact tracing and preventive treatment are important aspects of TB 
control in low-burden countries. In New Zealand, TB is a notifiable disease, meaning all 
cases are reported to the Medical Officer of Health (19). TB in New Zealand is treated by 
secondary care providers. Hospital or home isolation during initial treatment stages is 
mandatory for infectious cases. DOT is not always utilised, although some form of treatment 
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monitoring takes place. Public Health Units are responsible for community-based contact 
tracing, testing and LTBI preventive treatment where applicable.   
Tuberculosis prevention 
Case finding and treatment serves to prevent transmission and further cases of TB. This is the 
main preventive strategy in use in the world. Other preventive measures include infection 
control (particularly in the case of health care workers), contact tracing and treatment, LTBI 
treatment, and vaccination (1).  
Latent tuberculosis 
Identifying and treating LTBI can prevent progression to TB, in turn preventing further 
transmission (16). Unfortunately, no gold standard diagnostic test exists. In practice LTBI is 
defined as a positive immunological test (IGRA or TST), in a person with no radiological or 
clinical manifestations of TB. A positive IGRA is associated with a five-fold increase in the 
risk of future TB (22), however the positive predictive value of IGRAs are only 3.3% (23). 
The risk of progression is higher in certain populations such as those recently infected, the 
immunocompromised and young children (16). Treatment is recommended in these groups. 
However, in healthy populations the number needed to treat to prevent a case is higher, and 
there is no currently reliable biomarker or other measure to accurately predict who will 
develop TB. Therefore the WHO only conditionally recommends that migrants from high to 
low burden countries are screened and treated for LTBI (24). Migrants to New Zealand from 
high incidence countries are not routinely screened for LTBI, although this is conditionally 
recommended in national guidelines (25). Nine months of daily monotherapy is the standard 
treatment regimen and is highly effective, although adherence is often poor. Side effects, 
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such as drug-induced hepatotoxicity may occur with isoniazid use, necessitating monitoring 
of liver function tests during treatment, and in some cases treatment cessation. There is 
increasing evidence as to the efficacy and safety of shorter combination therapies and these 
may improve uptake and treatment of LTBI (26).  
Vaccination 
Vaccinating infants against TB with the Bacillus Calmette-Guerin (BCG) vaccine is widely 
practised in high-incidence countries. BCG is effective for prevention of childhood miliary 
and meningeal TB (27). There is some evidence of protection against TB infection and 
pulmonary TB (28,29). New Zealand does not routinely vaccinate children with BCG, 
although infants living in a household with a person with a history of TB, or who have 
recently lived in a high burden country are recommended vaccination. Vaccination is also 
recommended for New Zealand children who will be, or are expected to be living for more 
than three months in a high burden country (30). New vaccinations are being developed, with 
some promising results, however these are not currently licensed for use outside of clinical 
trials (31).   
Migrants and tuberculosis  
Global migration 
International migration for the purposes of employment, study, or to escape war and 
persecution is at the highest level ever seen, with 244 million people living outside of their 
country of birth in 2015. Seventy-five percent of these migrants were born in a low or 
middle-income country, and many settle in a high-income country (32). Half of all migrants 
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in 2015 were living in a high-income OECD country, and the current level of migration to 
these countries is at the highest rate since 2007 (15). In 2015, the number of worldwide 
refugees was the highest recorded since World War II. Whilst OECD countries do not take a 
large number of refugees by world standards, the impact is still significant, with 1.6 million 
applications for asylum lodged in the OECD in 2016. 
Migration and tuberculosis epidemiology 
Diseases move with people across national borders. The OECD comprises 36 countries 
including New Zealand, most of which are low TB-incidence countries. In seventeen OECD 
countries, more than half of the TB notifications originate from foreign-born persons, and in 
some nations this figure nears 90% (33). To illustrate how migration impacts TB control in 
OECD countries we plotted the relationship between the percentage of TB in people born 
overseas and the mean annual percentage change in TB incidence for OECD member states 
(Figure 1) (7,8,34–38). In general, recent reductions in incidence is greatest in countries 
where most TB cases are locally born, and incidence is higher than other member states. 
Conversely reductions in TB incidence are more modest in countries with a high proportion 
of TB cases occurring in migrants. TB incidence needs to decline by 12-20% per year in low 
prevalence countries to meet  TB elimination targets, but none of the OECD countries are in 
this range (6). This reflects the difficulty in making improvements on already low incidence 
rates, and the need for strategies that specifically target migrants in high migrant receiving 
developed countries.  
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Figure 1. Percentage of tuberculosis in foreign-born and mean annual change in tuberculosis 
incidence 
Information sourced from European Centre for Disease Prevention and Control Tuberculosis 
surveillance and monitoring in Europe 2017, and from individual countries’ annual tubercolosis 
reports. Mean annual percentage change for European countries from 2011-2015, Australia from 
2008-2013, Canada 2010-2014, Japan 2012-2015, New Zealand 2010-2014, United States 2012-2016. 
Percentage of TB cases in European countries from 2015 data, Australia 2013, Canada 2015, Japan 
2015, New Zealand 2014, United States 2016 TB= tuberculosis, UK= United Kingdom, USA= United 




The contribution of migration to TB risk in low incidence countries is evidenced by higher 
incidence in migrants than locally born individuals. Table 1 shows the incidence of TB in 
both foreign-born and non-foreign born in selected low incidence jurisdictions where that 
data are available. Many of these countries are approaching the pre-elimination rate of <1 per 
100,000 in their non foreign-born population yet due to higher rates in the foreign-born 





























































0 20 40 60 80 100
Precentage of TB cases in people born overseas
Incidence>10 per 100,000 Incidence</=10 per 100000
 13 






TB Incidence per 
100,000 in foreign-
born people 
TB incidence per 
100,000 in non foreign-
born people 
Australia, 2013 (7) 5.5 18.4 1.0 
Canada, 2015 (34) 4.6 14.8 1.6 
England, 2016 (39) 10.2 49.4 3.2 
New Zealand, 2016 (2)  6.3 17.7 1.9 
Scotland, 2016 (40) 5.7 45.3 2.3 
United States, 2016 (37) 2.9 14.7 1.1 
Note: For England and Scotland, ‘foreign-born’ and ‘non foreign-born’ in this table refers to those 
born outside, and in the United Kingdom respectively. USA= United States of America, TB= 
tuberculosis 
 
Multidrug-resistant tuberculosis in migrants 
In addition to having higher rates of TB, migrants also have higher rates of drug resistant TB 
than non-migrants. MDR-TB is seen in only 1-4% of cases in low-incidence OECD countries 
however the proportion seen in migrants is often higher than their overall contribution to TB 
incidence would suggest (2,7,8,37). Cases of MDR-TB in Europe often originate from former 
Soviet Union countries (41–43), which have the highest rates of drug resistance in the world 
(1). In terms of absolute numbers of MDR-TB cases, China, India and Russia account for 
almost half of the global total (1), and migration from the former two countries to the OECD 
is high (15). In New Zealand, 86% of MDR-TB in foreign-born people is seen in those born 
in Asian countries (2). MDR-TB is particularly important because of the high costs (12) and 




Although TB is more common in migrants than the native-born population of low-incidence 
countries, transmission outside migrant communities is uncommon. Analyses using 
molecular typing in the United Kingdom (44), Israel (45), and Europe (46–49) have found 
that despite an increase in TB related to migration, transmission to the host population is 
negligible, or of the same magnitude as transmission between non-foreign born people. A 
Danish study found that those born in Denmark are more likely to infect migrants with TB 
than vice versa (50). In contrast, a Rhode Island study showed limited transmission, with 
foreign-born source cases for a majority of those in mixed clusters (51). Interestingly, a 
recent re-analysis using whole genome sequencing concluded that transmission may be 
overestimated with standard genotyping, resulting in even less risk to a local population from 
migrant related TB (52).  
Transmission within certain migrant groups in low-incidence countries is likely to occur at a 
higher rate than transmission from migrant to native peoples. Larger numbers of clustered TB 
cases have been documented in Somalis in Denmark (53), Senegalese and Peruvians in Italy 
(54,55) and Pacific Islanders in New Zealand (2), and may reflect social interaction and 
integration into a host country. Being a part of a cluster is often taken as evidence of 
transmission, however this is not necessarily the case; common endemic strains from the 
country of origin may reactivate contemporaneously, resulting in cases being designated as a 
cluster (39). Second generation migrants (non-foreign born children of migrants) are also at 
higher risk (56). 
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Migrants’ social vulnerability and tuberculosis 
Migrants are a heterogenous group who move to a new country for a variety of reasons. 
Many could be considered ‘vulnerable’ members of society (32), with employment, social 
integration and economic constraints commonly described by groups of both migrants and 
refugees (57,58). Poverty and social inequalities faced by many migrants interplay with TB in 
a multitude of ways. Firstly, reactivation of LTBI may be promoted due to poor living 
conditions in a new host country (59), or through the resettlement journey in the case of 
refugees (60). Transmission of TB is increased within certain migrant communities, with 
living conditions (in particular overcrowding) possibly contributing to this (61). As well as 
cost being a barrier to accessing health care, other factors such as stigma, fear of TB 
prejudicing immigration decisions, language barriers, a lack of understanding of TB and 
attitudes of health care workers may contribute to a delay in seeking treatment. This in turn 
increases morbidity and transmission risk amongst migrants (60,62,63). Finally, a diagnosis 
of TB may lead to significant costs (direct and related to productive time lost) faced by 
migrants (21) which may further perpetuate the social vulnerabilities discussed above.  
Conclusion 
Migration is an important driver of TB rates in high-income countries. In many of these 
countries, foreign birth is the predominant risk factor for TB, accounting for a 
disproportionate number of cases. Migrants diagnosed with TB in low-burden countries have 
higher rates of drug resistant TB, making treatment a challenge. Migrants are economically 
and socially vulnerable, resulting in increased risk, and consequences of TB. Transmission 
from migrants to the non-foreign-born population is rare, but transmission between migrant 
groups and families is common, perpetuating inequities and increasing costs for the health 
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system. The WHO End TB strategy calls for low incidence countries to aim for TB 
elimination and further reduce disease rates; a focus on risk groups, especially migrants will 
be paramount in achieving this. 
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Chapter 3: Tuberculosis screening in low incidence countries 
Introduction 
Disease screening is defined as the presumptive identification of unrecognised disease in an 
apparently healthy, asymptomatic population by means of tests, examinations or other 
procedures that can be applied rapidly and easily to the target population (64). Many low-
incidence countries screen for TB in incoming migrants, usually with the aim of detecting 
active, and potentially infectious pulmonary TB through chest x-ray screening, although 
some also screen for LTBI. While no two countries have identical screening programmes 
(9,65–67), programmes can be categorised according to whether screening occurs on arrival, 
pre-arrival and post arrival. Most countries perform screening on arrival. New Zealand is a 
member of The Immigration and Refugee Health Working Group (IRHWG), along with 
Australia, Canada, New Zealand, United Kingdom and United States. IRHWG countries have 
pre-arrival screening. Post arrival screening refers to continued follow up of those who had 
an abnormal screen but in whom TB was not confirmed. These are discussed below.  
On-arrival screening 
Most European OECD nations undertake TB screening at the time of arrival. There is 
variance in which migrant groups are screened (refugees, asylum seekers, or all migrants) 
(9,66,67). Screening may occur at the port of entry, dedicated immigration or refugee centres, 
or in the community soon after arrival (68). Migrants seeking asylum have increased in 
Europe in recent years, with some countries performing mandatory (69,70), or voluntary (71) 
screening in this group.   
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The yield of on-arrival screening of migrants from countries with TB incidence >50 per 
100,000 in European OECD countries and some IRHWG countries was assessed in a meta-
analysis in 2010 (72). Pulmonary TB was detected in 270 per 100,000 regular immigrants, 
280 per 100,000 asylum seekers, and 1,190 per 100,000 refugees. Asian and African 
immigrants had a higher incidence of TB than those from Europe, likely reflecting the higher 
incidence of TB in these areas. Screening migrants from low incidence countries had much 
lower yields. In 2015, the Netherlands stopped screening migrants from countries with an 
incidence of <50 per 100,000 as screening yield was only 26 per 100,000 (73). Screening 
programmes may differentiate according to category of migrant, for example asylum seekers 
have been recognised as a lower yield target population in Europe, as lower incidence 
countries such as Syria and Iraq are the main origin countries.   
Pre-arrival screening 
Immigration screening procedures in Immigration and Refugee Health Working Group 
countries 
TB screening in New Zealand is similar to that occurring in the other IRHWG countries of 
Australia, Canada, United States and the United Kingdom (Table 2). These countries 
collaborate on migrant health care and screening including for TB. Each country has similar, 
mandatory screening processes for potential migrants, and collectively screen approximately 
two million migrants and visitors annually (74). Visa applicants are required to undergo pre-
entry screening, at offshore, approved sites, by designated doctors called ‘panel physicians’. 
The development of these offshore screening facilities has required significant capacity 
building by IRHWG countries in high burden countries. Migrants already in their destination 
country (for example, visitors who then apply for residency) may be screened by onshore 
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panel physicians, using the same procedures. Medical examination and x-ray screening are 
required, and those with a suspicion of TB (symptoms, past history or x-ray abnormalities) 
undergo sputum smear and culture testing. Positive cases must undergo treatment before visa 
approval. Slight differences exist in screening protocols between the five countries, which are 
described in table 2. Table 3 describes screening yield and numbers needed to screen to 
detect one case. There are no New Zealand data as to yield and numbers needed to screen.  
Table 2. Pre-arrival tuberculosis screening in Immigration and Refugee Health Working Group 
countries. 
Country (reference) Pre-entry screening* for 
permanent migrants 
Pre-entry screening* for 
temporary migrants 
Australia (75) Required from all countries   Required if staying ³6months from 
high risk countries  
Canada (76,77) Required from all countries  Required if staying ³6months from 
high risk countries  
New Zealand (78) Required from all countries  Required if staying ³6months from 
high risk countries  
United Kingdom (79) Required from a country 
with TB incidence 
³40/100,000  
Required if staying ³6months, 
from a country with TB incidence 
³40/100,000  
United States (80) Required from all countries  Not required  
* Physical examination and chest radiograph. Note chest radiograph not routinely required in those 
<11 years old (Australia, New Zealand, United Kingdom), those <15 years old (United States). Age 










Table 3. Off-shore pre-migration tuberculosis screening yield and numbers needed to screen. 
Country, years (reference) Yield per 100,000 
people screened 
Number needed to 
screen 
United States, 2007-2012 (81) 258  388 
United Kingdom, 2016 (79) 101 990 
United Kingdom, 2005-2013 (82) 92 1,087 
Canada, 2008-2011 (83) 106 943 




Risk factors for tuberculosis in migrants identified through pre-arrival screening 
A multi-country analysis of pre-arrival TB screening of migrants reviewed fifteen studies 
from OECD countries (mostly United States, Australia and Canada), and found that the yield 
of screening increased in proportion to the incidence of TB in the country of origin (85). In 
the United Kingdom, Aldridge et al (82) analysed nearly 500,000 offshore screening results 
of visa applicants from high-risk countries between 2005 and 2013. On multivariate analysis, 
migrants applying for a settlement and dependant visa had a 30% increased risk of TB 
compared with those applying for a student visa. Coming from a country with a lower 
incidence of TB (40-149 per 100,000) was found to be associated with a 90% lower risk of 
TB than in those coming from countries with rates of 150-349 per 100,000. There were 
discrepancies with the highest incidence bracket of ³350 per 100,000 having a 70% lower 
incidence of TB compared with those coming from countries with a rate of 150-349 per 
100,000. The authors do not postulate any reasoning for the lower yield from countries in the 
highest incidence bracket but do comment that migrants from low-burden countries are at 
reduced risk of TB and that the cost-effectiveness of screening should be considered in this 
context.  
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In Canada, over 300,000 immigration medical assessments for those seeking residency in 
Ontario were reviewed (83). Of those who actually settled in Ontario, TB was detected in 47 
per 100,000 medicals. Eighty-seven percent of these cases were in people who emigrated 
from six high-burden countries: Afghanistan, China, India, Pakistan, Vietnam and the 
Philippines. Screening in over 114,000 people from regions with a weighted TB incidence 
rate of <50 per 100,000 resulted in only three TB diagnoses. No TB was seen in over 27,000 
migrants from New Zealand, Australia, United States, and Western Europe. Due to the 
significant costs borne by the government, health authorities and the individual, the authors 
argue that screening should focus on those coming from high-risk countries and cease in 
those from low-risk countries.  
An Australian analysis of offshore immigration medical examinations performed between 
2009-2010 found that TB was diagnosed in 137 per 100,000 immigration medical 
assessments (86). Over 60% of cases came from four countries: Philippines, China, Vietnam 
and India. In the top ten source countries, some (Philippines, Vietnam, Cambodia and Nepal) 
had significantly higher incidence of TB than the WHO country estimate would suggest; in 
others (India, China, South Korea, Indonesia), the screening incidence was lower, or even 
half of the respective country estimate. This suggests that other factors in addition to 
incidence in the country of origin influence TB risk in migrants. This is important to 
acknowledge if TB screening programmes are to focus their screening efforts on those 
coming from high risk countries, as suggested by some authors (83).  
In the United States, notification data during 2007-2012 was analysed. There were 258 per 
100,000 TB diagnoses made overseas (81). Ninety-three percent of these cases were from 
countries with a TB incidence rate of >100 per 100,000, yet these countries made up just 
under half of all migrants.  
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These studies show that groups at higher risk of TB can be identified within the migrant 
cohort.  
Addition of culture to screening algorithms 
All IRHWG countries now require TB culture to be performed in those with a chest x-ray 
suggestive of TB. The United States changed screening requirements in 2007 to incorporate 
sputum culture testing whereas previously only sputum microscopy was required. A study to 
examine the effect of this change found that before 2007, annual TB cases amongst foreign-
born people within one year of arrival were steady at approximately 1500 (81). During 
implementation of culture-based screening, case numbers fell rapidly to 940. The decline in 
case numbers is similar to the number of smear negative, culture positive cases diagnosed 
overseas in the same timeframe. In this study, migration rates and temporal changes in TB 
incidence in origin countries have not been adjusted for. Despite this, the authors (87), and 
others (88) conclude that pre-entry screening using a culture-based algorithm has increased 
the number of cases diagnosed overseas and reduced the incidence of TB in migrants to the 
United States.  
Impact of pre-arrival screening 
From 2006 to 2016, participation in offshore screening grew from five to 101 countries 
performing offshore screening for those migrating to the United Kingdom (39). During this 
time the absolute numbers of cases of pulmonary TB within one year of arrival in England 
reduced from 380 to 57, and the ratio of cases identified overseas to those in the United 
Kingdom has significantly increased (79). Similar to data from the United States, this 
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suggests that offshore screening is effectively reducing the burden of TB in migrants by 
detecting and treating disease in the country of origin pre-migration. 
Drug resistant tuberculosis and pre-arrival screening 
MDR-TB detection is an important aspect of pre-entry screening, given the public health 
implications and cost involved in treatment. Pre-arrival screening in those migrating to 
Australia, where drug susceptibility testing was performed, found an MDR-TB rate of 3% in 
2012 and 11% in 2013 (7). In pre-arrival screening in those migrating to the United States in 
2014, 44/1450 (3%) cases of MDR-TB, and 1/1450 (<0.1%) XDR-TB cases were detected 
(74). In those migrating to the United Kingdom between 2007-2016, 11/621 (2%) of positive 
cultures were MDR-TB and 1/621 (0.2%) were XDR-TB (79). However, in some years only 
half of all cultures were tested for drug susceptibility due to limitations in off-shore 
laboratory capacity. 
Post-arrival screening 
Systematic follow up of migrants deemed to be at higher risk of developing TB is known as 
post-arrival screening. Migrants with chest radiograph abnormalities, in whom 
microbiological tests for TB are negative have a higher incidence of developing TB after 
migration. Incompletely treated, or early, undetectable active TB may result in these 
radiologically abnormalities which develop over time to more overt TB (89,90). In over half 
a million people who completed pre-entry screening before migration to the United Kingdom, 
those with an abnormal screening x-ray (but negative TB cultures) were three times more 
likely to develop TB than those with a normal x-ray (44). Chan et al (91) performed a meta-
analysis looking at ‘high risk migrants’, many of whom had an abnormal x-ray but were not 
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diagnosed as having TB at pre-arrival screening. After migration, TB was found in 2,794 per 
100,000 person years of follow up. The incidence of TB in those attending an arranged, first 
surveillance visit post-migration was even higher at 3284 per 100,000. While a direct 
comparison was not made in the study, this incidence rate is tenfold higher than the rate in a 
pre-arrival screening meta-analysis (85). Migrants with pre-arrival screening abnormalities, 
in whom a diagnosis of active TB has been excluded, are at high risk of developing TB after 
migration.  
To this end, Canada, United States and Australia – all countries with well-developed pre-
arrival screening programmes - have introduced systematic, formalised follow up for this 
group after migration (Table 4). This involves scheduled clinic visits for clinical and 
radiological follow up. New Zealand and the United Kingdom do not have any systematic 
screening for those deemed to be at increased risk post-arrival.  
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Table 4. Post-arrival tuberculosis screening in Australia, Canada and United States. 
Country 
(reference) 
Indication for screening* Process Compulsory or voluntary Compliance rate 
Australia 
(84,92) 
Previous treatment for TB or 
abnormal chest radiograph  
Migrant signs a ‘TB Health 
Undertaking’, agreeing to contact 
health authorities within 28 days 
of arrival  
Compulsory. Non-compliance results 
in a migrant not meeting the 





History of TB or x-ray 
changes of old healed TB or 
inactive TB  
Must report to health authority 
within 30 days of arrival  
Not compulsory for residence, but is 





(80,81)   
Signs, symptoms, or chest 
radiograph changes 
suggestive of TB or HIV 
infection  
State and local health departments 
are notified and conduct follow up   
Unclear 68%  
*Criteria applies for all countries when active TB has been excluded by sputum smear and culture. Migrants are allowed to enter their destination country, 
with follow up as described. TB= tuberculosis, HIV = human immunodeficiency virus. 
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Programmatic data from countries with post arrival screening 
In Alberta, Canada, 2% of migrants were referred for post arrival screening between 2002-
2013. The incidence of TB in those referred was nine times higher than in those not requiring 
follow up. The programme diagnosed TB cases earlier, meaning those referred had were 
mostly asymptomatic, had less chest x-ray cavitation, less smear positivity, less disseminated 
disease and were responsible for a lower rate of transmission than those not referred to the 
programme (77). Similar findings were seen in Ontario, where those who were referred and 
compliant with screening had a higher rate of TB and shorter duration of symptoms (83).  
In the United States, two-thirds of people with an x-ray suggestive of TB and normal 
microbiological tests completed follow up, with 1,804 per 100,000 being diagnosed with TB. 
It was estimated that if all people in this group completed follow up in 2012, 300 cases of TB 
would have been diagnosed – approximately one third of the reported TB cases in foreign-
born persons in the United States (81).  
In Victoria, Australia migrants with abnormal x-rays in whom TB has been ruled out indicate 
they will comply with post arrival follow up as part of what is termed a ‘health undertaking’. 
This programme diagnosed TB at a rate of 420 per 100,000 migrants within six months of 
entry (93). 
Although those with abnormal x-rays and normal microbiological tests are a high-risk group 
of migrants, post-arrival screening only identifies a small portion of foreign-born TB overall. 
In Ontario only one out of forty foreign-born TB cases were detected through post-arrival 
surveillance (83), and in Alberta screening did not identify 80% of foreign-born TB cases 
(77). Post arrival screening appears to be a useful adjunct to pre-entry screening, but clearly 
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other methods will need to be employed to reduce migrant related TB in low incidence 
countries.  
Latent tuberculosis screening 
In the context of radiological screening most TB in migrants is caused by reactivation of 
remotely acquired infection, often presenting years after migration (33). Screening and 
treating migrants for LTBI can prevent future TB, and is conditionally endorsed by the WHO 
in low-incidence countries (24). However, most countries do not systematically screen for 
infection. Australia screens children migrating from countries with an incidence ³40 per 
100,000 (74,75) and United States screens children migrating from countries with an 
incidence ³20 per 100,000 (80). The United Kingdom has recently introduced a guideline to 
screen those aged 16-35 arriving from countries with an incidence ³150 per 100,000 (94). 
Cross sectional studies of M. tuberculosis infection in migrants, diagnosed by IGRAs have 
found 16-50% prevalence (39,95–98) with a correlation between positivity and higher TB 
rate in the country of origin (95,98,99). The risk of progression to active TB among migrants 
varies significantly between studies. In the United Kingdom, 14% and 16% of 16-34 year old 
migrants with LTBI developed active TB within 10 and 15 years of follow up respectively 
(100). In contrast, Southeast Asian refugees to Australia had a much lower rate of 
progression, at 0.12% per year (101).  
There are no studies of the public health impact of treating LTBI in migrants, perhaps 
reflecting that this is not yet established practice in many settings, and the long time to see 
the impact achieved. However, many programmes have been evaluated using an operational 
research framework called the ‘cascade of care’. This describes the process of LTBI 
 28 
screening and treatment as comprising multiple steps, from screening acceptance, referral, 
treatment recommendation and acceptance, and treatment completion (102). Reports describe 
many drop-offs along this cascade, potentially reflecting physician and patient attitudes, 
funding or service capacity (103). In the United Kingdom, rates of treatment acceptance 
ranged from 22-82%, and treatment completion 27-98%, depending on location (39). In 
Australia, 22% of those with LTBI were not offered treatment, 14% of people refused 
treatment, and 10% of people started but did not complete treatment (104). In Norway, 
multiple dropouts along the cascade resulted in only 1% of over 2000 patients with possible 
LTBI commencing treatment (105). In spite of this, good results can be achieved from LTBI 
screening and treatment programmes. In two studies in United States, greater than 90% of 
refugees completed treatment for LTBI (106,107). 
The United Kingdom recently recommended LTBI screening and treatment in migrants from 
high-incidence countries (94), however the impact is not yet known. Pareek et al concluded 
that screening migrants under 35 years old from countries with a TB incidence of greater than 
150 per 100,000 would identify 92% of those with LTBI and would be highly cost effective 
(98). Another analysis found that overseas LTBI screening and treatment of refugees in 
countries with high or moderate LTBI rates could avert 220-440 cases per 100,000 entries 
over the following twenty years, offsetting the cost of screening (108).  
Conclusions 
No two countries have identical procedures for screening incoming migrants for TB. 
Similarities exist, particularly between the IRHWG countries of New Zealand, United States, 
United Kingdom, Canada and Australia. These countries all perform pre-arrival screening 
that has an approximate yield of 100-200 per 100,000 visa applications and has been shown 
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to reduce TB incidence in the destination country. Post-arrival follow-up identifies further 
cases in high-risk patients, often before they are symptomatic. Still, the bulk of TB in the 
foreign-born in low-incidence countries is due to reactivation of LTBI, and movement 
towards elimination will only proceed if this is addressed. Uptake and adherence to LTBI 
treatment is variable but can be high in some settings and is estimated to be cost-effective.  
Screening migrants from low-incidence TB countries has a poor yield, with some authors 
calling for abandonment of widespread screening in order to focus on those at higher risk 
(83). Targeting screening to specific groups, such as those migrating from high-burden 
countries and refugees, or other risk factors may increase the effectiveness of screening 
programmes. 
Ultimately, while the burden of TB is high in source countries, migration will continue to 
drive disease rates in low-incidence countries. A multifaceted approach to migrant related TB 
in low-incidence countries, including targeted pre-entry screening for active and latent 
disease, follow up of those with risk factors and efforts to improve global TB control will be 
required to move towards elimination.  
Little is known about specific risk factors in migrants to New Zealand, and New Zealand’s 
screening programme has not been formally evaluated. Study of risk factors and the 
performance of screening will provide information to improve current screening practices and 




Chapter 4: Integrated Data Infrastructure cohort study – 
methods   
Introduction 
Information on risk factors for TB in migrants to New Zealand are needed to guide 
prevention efforts.   
Objective 
To calculate annual TB incidence in migrants to New Zealand according to nationality and 
visa category, and to calculate incidence of TB using a person-time analysis.  
Study design 
TB notifications were linked to the Statistics New Zealand Integrated Data Infrastructure 
(IDI) dataset, to create a cohort of migrants to New Zealand followed from entry until either 
notification of TB, final departure from New Zealand, or the end of the study period. 
Incidence and relative risk of developing TB was calculated according to nationality, age, sex 
and visa type. 
Setting 
New Zealand between 01/01/2007 and 31/12/2016.  
 31 
Description of the dataset 
IDI: The Statistics New Zealand IDI is a database containing data about people and 
households in New Zealand. A range of government and non-government agencies input data 
into the IDI. Broad categories of data in the IDI include health, migration, justice, education, 
housing, income and work, and social services data.  
The IDI captures all individual border movements in and out of New Zealand (including New 
Zealand nationals, permanent and temporary migrants) and all visa applications since 1998. 
Data are collected by Immigration New Zealand (INZ) from visa application forms and 
electronic passenger movement records. Data are extracted biannually and added to the IDI 
by Statistics New Zealand (109). Nationality and travel dates are recorded for each 
individual. Visa category is recorded for each arrival in the IDI, with the exception of those 
not requiring a visa (i.e. those travelling on a New Zealand passport). 
TB cases: TB cases were obtained from notification records. Under Section 74 of the Health 
Act 1956, TB is a notifiable disease in New Zealand (110). Clinicians and laboratories must 
notify the Medical Officer of Health of suspected or confirmed TB. Data is then entered into 
the national database (EpiSurv) which is collated by the Institute of Environmental Science 
and Research (ESR) on behalf of the Ministry of Health (111).   
Requested fields from notification data related to disease type (latent TB, reactivation or 
relapse), National Health Index (NHI) number, basis of diagnosis, pulmonary or 
extrapulmonary disease, outbreak and transmission details, notification date and TB-specific 
risk factors. 
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Linkage: One dataset, known as the ‘spine’, links to all other datasets in the IDI. The spine 
combines data from three sources – tax, births and visas, to capture the resident population of 
New Zealand as accurately as possible. Certain visa categories, particularly those associated 
with living, studying or working in New Zealand, are automatically linked to the IDI spine 
(Table 5). Data cannot be linked across different datasets without linking through the spine. 
TB cases were linked to the IDI using the NHI by Statistics New Zealand. NHIs supplied by 
ESR are linked to existing health data in the IDI. This data is then linked to the spine, and 
then further linked to visa data by probabilistic matching, using name, date of birth and sex as 
matching variables. A unique identifier is allocated to each individual (112). 
Inclusion criteria 
Participants in this study are migrants to New Zealand, defined as any person issued a 
resident, permanent resident, work, limited or student visa and who arrived in New Zealand 
for the first time on an included visa between 01/01/2007 and 31/12/2016.  
The permanent resident, resident, work, limited and student visa categories are all in the IDI 
spine (Table 5). Only the ‘endorsement’ category allows a person to be resident in New 
Zealand but not in the spine. These are people who are New Zealand citizens but travel on a 
foreign passport. Refugees granted asylum in New Zealand enter on a resident visa and are 
included in the spine; those who enter New Zealand and apply for asylum keep their entry 
visa until their claim is processed. Temporary visa categories that do not confer the ability to 
work or study in New Zealand include visitors in addition to those listed in table 5.  
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This definition does not include short term visitors because TB may not be diagnosed in a 
short visit as it is a slowly progressive disease. Short-term visitors are also unlikely to be in 
the IDI spine and therefore would not be able to link to health data.  
Australians are allowed to travel to New Zealand without restriction for residence, work or 
study. The visa categories Australian or Resident are used interchangeably on arrival, 
therefore it is not possible to distinguish between Australians entering New Zealand for 
residence, work or holiday and they are excluded from the migrant cohort.  
People living in Realm of New Zealand countries – Niue, Cook Islands, and Tokelau, are 
essentially New Zealand citizens, and may travel on a New Zealand passport. They are not 
included in the migrant cohort in this study.  
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Table 5. Visa type and characteristics in the Integrated Data Infrastructure dataset. 
Visa characteristic Included in IDI spine Visa type 
Allowed to permanently live 
in New Zealand 





Temporary visa, can study 




Temporary visa, cannot 
work or study in New 
Zealand 









* These visa categories allow a person to live in New Zealand, working for their home government in 
diplomatic or consular roles. Thus, they are not officially working (or permanently residing) in New 
Zealand. IDI= Integrated Data Infrastructure
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Definitions 
Confirmed and probable TB cases 
TB cases are either confirmed or probable cases. A confirmed case of TB in New Zealand is 
defined as a clinically compatible illness with laboratory confirmation by any one of: positive 
culture of M. tuberculosis, positive microscopic examination for acid-fast bacilli, positive M. 
tuberculosis nucleic acid or positive histology. A probable case is not laboratory confirmed, 
but has signs and symptoms compatible with active TB and full anti-tuberculosis treatment 
has been commenced by a clinician (19). 
Variables 
The following variables were analysed as potential risk factors for TB in migrants to New 
Zealand.  
Nationality 
International literature frequently classifies migrants based on nationality, or country of birth. 
In this study nationality is defined according to the origin of the passport or travel document 
used to enter New Zealand. Nationality probably reflects TB risk more accurately than 
country of birth as it is assumed that a migrant has spent considerable and recent time in that 
country prior to migration. Once analysed, it was apparent that birth country was poorly 
entered in the IDI, with approximately 50% missing records. Port of embarkation is not 
suitable to use to define the country of origin for a disease with long latency like TB, as only 
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World region was assigned according to migrant nationality and classified as European, 
North American, Latin American and Caribbean, Sub-Saharan African, North African and 
Middle East, South Central Asian, South East Asian, North East Asian and Pacific. I refined 
categories from that presented in the ESR Annual TB report (2016) (2). The region 
‘Americas’ from the ESR report was divided into North America, and Latin America and 
Caribbean. This classification avoids combining high prevalence Asian countries with lower 
prevalence Pacific countries that occurs when WHO regions are used. Simpler, intuitive 
geographical regions were therefore used. See appendix for a list of countries and regions. 
TB incidence in country of origin 
 
I assigned the incidence in a migrant’s country according to the WHO 2016 incidence 
estimates (1), with country defined as nationality as described above.  
Visa category  
 
Visa categories were assigned using immigration arrival tables in the IDI. In those who 
arrived on a temporary visa and then changed visa (for instance arrival as a visitor, and then 
applied for residence), visa application categories were used. Visas were categorised as 




Age, sex and year of arrival as recorded in the IDI were also analysed.  
Analysis 
For each person in the cohort, all arrivals and departures subsequent to the index arrival were 
used to calculate the total number of days present in New Zealand during the study period. 
For migrants who arrived on a visa not included in the study (such as visitors) and then 
changed to a visa included in the study, their index arrival was defined as their entry on the 
initial visa.  
Person-years at risk were used to calculate TB incidence and rate ratios by the above 
variables. Nationality is reported in terms of region of origin, and specifically for the top 21 
countries’ incidence rates. Aggregated data increases accuracy of incidence rates from 
countries with small numbers of migrants or TB cases and prevents inadvertent identification 
of TB cases from countries with very low numbers of migrants.  
Incidence in New Zealand was compared to incidence in the country of origin and reasons for 
differences in terms of migrant selection or screening considered. To understand the potential 
impact of LTBI screening of migrants at various incidence thresholds, cumulative numbers of 
migrants and TB cases were plotted by WHO incidence thresholds to indicate the likely yield 
of enhanced screening. 
Full multivariate analysis of these variables was performed. Because WHO incidence 
estimates are higher in some world regions than others, separate multivariate models were 
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developed using WHO incidence and world region. As TB incidence by visa category may be 
confounded by age (for instance those on student visas are likely to be younger than those on 
work visas), a separate analysis of these two variables was performed to assess this.  
This study adheres to Statistics New Zealand’s strict confidentiality rules allowing use, and 
publication of data from the IDI (113). All data from the IDI presented in this study has met 
these confidentiality rules and has been cleared for release by Statistics New Zealand. These 
confidentiality rules require that raw counts are randomly rounded to base three so exact 
numbers are not presented in this thesis. Due to this rounding, and the fact that rounding 
occurs separately for each data table, numbers sometimes do not add up to consistent totals 
(for instance, the total for all migrants from different world regions and the total for migrants 
with differing visas may disagree). Suppression of small counts (<6 individuals), and any 
statistic based on small counts is also required. In the case of a region with less than six TB 
notifications, all statistics for this region (including TB incidence) must be suppressed. 
Suppressed values in this thesis are shown as “<6”. 
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Chapter 5: Integrated Data Infrastructure cohort study - results 
Introduction  
This study is an analysis of a cohort of migrants to New Zealand. The cohort was constructed 
in the Statistics New Zealand IDI database using border movements data and TB notifications 
linked to the IDI.  
Derivation of study sample 
Participants 
The migrant dataset consisted of 1,597,077 individuals, with 1,545,861 (97%) entering New 
Zealand on a visa included in this study. The remaining 51,213 (3%) entered the country on 
an alternative visa, and then changed to one included in the study. Visitors consisted of 
49,493 (97%) of these visa-changes. There were a combined 2,851,287 person-years at risk 
over the study period. There were no missing values for visa category, or date of arrival by 
definition. Data were imputed based on visa category and region and reclassified for 13,101 
(0.8%) migrants with missing date of birth, and 14,919 (0.9%) with missing sex. Country of 
origin was missing for 27 (<0.01%) of migrants and undefinable for 48 (<0.01%) migrants 




TB notifications  
Over the ten-year study period, ESR received 2928 notifications of TB (Figure 2). These 
cases were linked to the IDI.  
Non-migrants accounted for 1065 (36%) notifications, with 693 (24%) born in New Zealand, 
and 255 (9%) arriving on a non-eligible visa according to the study criteria, with at least one 
entry under New Zealand nationality (i.e. dual passport holders). Another 117 (4%) people 
arrived on non-eligible visa according to the study criteria, without dual nationality. This 
group would include visitors. Those arriving before the study period accounted for 837 (29%) 
cases during the study period. There were no movement data, and no notification arrival date 
for 60 (2%) cases. There were no movement data, and a notification arrival date within the 
study period for 84 (3%) cases. It is possible that these people were unable to be linked to the 
IDI spine and have thus been inappropriately excluded from the study. There was no 
Statistics New Zealand unique identification available for <6 of the TB notifications and thus 
these cases could not be linked to the dataset. There were <6 cases who had more than one 
tuberculosis notification and were excluded (exact numbers suppressed). After these 






Figure 2. Derivation of study sample for Integrated Data Infrastructure cohort study - tuberculosis 
notifications. 





Characteristics of migrant cohort 
Eleven percent of the cohort had a stay in New Zealand for six months or more prior to re-
entering New Zealand on a long-term visa type included in this study.   
Age and sex of migrants 
The age and sex of migrants is shown in table 6. Migrants aged 15-34 accounted for 
1,075,185 (67%) migrants. Those aged 35-54 made up 291,882 (18%) migrants. Males 
accounted for 833,781 (52%) migrants in the cohort. 
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Table 6. Age and sex of migrant cohort. 
Age band (years) Number Percent 
0-4 31,986 2.0 
5-14 101,793 6.4 
15-34 1,075,185 67.3 
35-54 291,882 18.3 
³55 96,225 6.0 
Total  1,597,077 100.0 




Female 763,296 47.8 
Male 833,781 52.2 
Total  1,597,077 100.0 
Total in age column does not add up to 1,597,077 due to random rounding. Correct total is provided 





Annual migration by region and country 
The annual number of migrants by world region is shown in table 7. The highest number of 
migrants were from Europe, with 571,599 (36%) migrants, and 771,777 person-years at risk 
(27%). The second highest numbers were from North East Asia, with 294,621 (18%) 
migrants and 469,068 (16%) person-years at risk. There were 119,496 migrants from the 
Pacific (7%) corresponding to 349,650 (12%) person-years at risk. From 2007 to 2016, large 
increasing in migrants from North-East Asia, South-Central Asia and South-East Asia were 
seen. 
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Table 7. Number of long-term migrants entering New Zealand according to year of entry and region of origin. 
Region Arrival Year 
 
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total 
            
Europe 54,159 54,702 54,360 51,039 54,345 51,255 55,806 61,410 65,253 69,276 571,599 
Latin America and Caribbean 5,517 6,168 5,997 5,187 5,076 4,638 5,127 6,090 6,822 6,930 57,546 
North America  11,961 12,351 12,339 12,324 11,928 11,340 12,342 12,963 13,431 13,890 124,866 
North Africa and Middle East 1,683 2,349 2,418 2,112 2,409 2,178 2,112 2,364 2,262 2,424 22,308 
North East Asia 24,393 25,098 25,359 25,119 25,536 26,634 27,792 32,889 39,567 42,237 294,621 
Pacific  12,033 14,694 13,404 10,290 11,721 10,992 11,664 11,652 11,253 11,793 119,496 
South Central Asia 10,290 13,068 14,076 15,381 14,394 15,603 16,785 24,699 29,178 23,871 177,345 
South East Asia 15,426 16,455 16,107 15,864 16,374 16,230 16,503 17,970 21,270 21,810 174,015 
Sub-Saharan Africa 6,450 7,845 6,258 5,406 5,259 4,479 3,942 4,161 4,782 6,621 55,206 
Missing <6 9 6 6 <6 6 <6 <6 12 9 75 
Total  141,915 152,739 150,330 142,728 147,051 143,361 152,073 174,201 193,824 198,858 1,597,077 




Country of origin for migrants from the 20 highest countries is shown in table 8. Great 
Britain had the highest number of migrants, with 232,980 (15%), followed by China (164,490 
migrants, 10%) and then India (145,176 migrants, 9%). The top 20 countries together 
accounted for 1,323,804 migrants, or 83% of the total. Migration from many of these 
countries significantly increased over the study period. For example, there were 8,700 
migrants from China in 2007, and 28,000 in 2016. In 2007, 8,500 migrants arrived from 
India, and in 2016 this number was 19,000.  
Regional migration is influenced by high migration from individual countries; China 
accounts for 56% of all migration from the North East Asian region, India 82% of migration 
from South Central Asia, United States 71% from North America, South Africa 83% from 
Sub-Saharan Africa. 
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Table 8. Number of long-term migrants entering New Zealand according to year of entry and country of origin, for the top twenty countries. 
 Arrival Year 
Country  2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total 
Great Britain 29,160 27,720 25,356 22,287 22,473 20,208 20,001 21,207 21,861 22,707 232,980 
China 8,694 9,873 11,148 11,400 13,893 15,765 17,019 21,453 27,087 28,161 164,490 
India 8,502 10,821 11,781 12,933 11,778 12,711 13,293 20,247 24,204 18,900 145,176 
Germany 9,249 10,485 11,091 11,016 11,457 11,454 13,890 15,219 16,572 17,661 128,094 
United States 8,757 8,712 8,550 8,625 8,493 8,148 9,012 9,384 9,267 9,705 88,653 
Philippines 5,271 6,765 5,526 4,965 5,517 5,973 5,901 7,416 9,903 9,642 66,873 
South Korea 7,701 7,746 7,332 6,762 5,562 4,812 4,446 4,614 5,031 5,730 59,736 
France 2,562 3,114 4,089 4,158 4,926 4,956 6,153 8,301 9,561 10,713 58,533 
Japan 5,571 5,439 4,821 4,869 4,170 4,146 4,335 4,758 5,202 5,901 49,212 
South Africa 5,112 6,399 5,022 4,479 4,491 3,717 3,258 3,420 4,026 5,772 45,693 
Fiji 5,178 5,724 5,595 3,627 3,660 3,189 3,261 3,519 3,792 4,014 41,556 
Samoa 2,991 3,465 3,891 3,528 4,218 4,245 3,924 3,951 3,495 3,498 37,203 
Malaysia 4,083 3,627 3,450 3,798 3,852 3,417 3,354 3,243 3,936 4,317 37,080 
Canada 3,009 3,354 3,450 3,330 3,081 2,808 2,928 3,144 3,669 3,726 32,499 
Ireland 2,565 2,622 3,030 2,865 4,023 3,267 3,528 3,339 3,183 3,108 31,530 
Tonga 2,769 2,490 1,974 1,620 1,851 1,659 2,502 2,307 2,307 2,421 21,903 
Thailand 2,283 2,205 2,526 2,355 1,869 1,761 2,061 2,214 2,256 2,268 21,801 
Indonesia 1,683 1,689 2,217 2,166 2,511 2,367 2,490 2,259 1,725 1,917 21,027 
Brazil 2,388 2,316 2,373 1,815 1,611 1,389 1,566 2,088 2,442 2,613 20,601 
Netherlands 2,064 1,938 1,815 1,827 1,818 1,653 1,692 1,854 2,127 2,376 19,164 
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Migration from the Pacific 
There were 119,496 migrants from the Pacific. Of these, the highest numbers of migrants 
came from Fiji (41,547 migrants, 35%), followed by Samoa (37,191 migrants, 31%) and 
Tonga (21,900 migrants, 18%).  
Annual migration and WHO estimated incidence rate 
Table 9 shows annual migration according to WHO estimated TB incidence. There were 
844,347 (53%) migrants from the lowest WHO incidence band (<40 TB cases per 100,000 
population), with 1,172,703 (41%) person-years at risk. Lower numbers of migrants arrived 
from countries with high TB incidence.
 47 






2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total 
            
<40 80,502 82,590 81,600 77,055 80,409 76,038 82,431 89,667 94,302 99,756 844,347 
40-149 35,352 38,754 38,328 35,529 36,966 37,218 38,706 44,052 52,107 55,371 412,383 
150-349 13,164 15,780 16,878 17,769 16,254 17,103 18,435 26,628 30,819 25,488 198,318 
³350 12,828 15,555 13,446 12,315 13,386 12,966 12,447 13,824 16,518 18,147 141,432 
Unknown 66 60 75 60 33 36 60 33 84 93 594 
Total  141,912 152,739 150,327 142,728 147,048 143,361 152,079 174,204 193,830 198,855 1,597,077 
WHO = World Health Organization. WHO incidence = 2016 WHO estimated TB incidence per 100,000 in country of origin. Data sourced from Global 
Tuberculosis Report 2017 - WHO 
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Annual migration and visa type 
The annual number of migrant arrivals by visa category is shown in table 10. Work visas 
accounted for the highest numbers of migrants, with 704,172 (44%), and the highest number 
of person-years at risk (1,014,126 migrants, 36%). Resident visas (including permanent-
resident visas) accounted for the second highest numbers, with 446,505 (28%) migrants and 
968,910 (34%) person-years at risk. Limited visas accounted for a lower proportion of 
migrants, with 84,084 migrants (5%) and 70,752 person-years at risk (3%).   
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total 
            
Resident 44,475 42,657 43,278 41,172 42,771 41,058 39,627 44,253 51,513 55,701 446,505 
Limited 4,698 8,652 8,679 7,731 9,045 8,907 10,365 9,918 8,475 7,614 84,084 
Student 29,901 35,625 36,039 35,751 32,994 30,057 30,177 41,139 47,217 43,416 362,316 
Work 62,841 65,805 62,334 58,074 62,241 63,339 71,904 78,891 86,619 92,127 704,172 
            
Total 141,915 152,739 150,330 142,728 147,051 143,361 152,073 174,201 193,824 198,858 1,597,077 
Resident group includes resident and permanent resident visas
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Characteristics of tuberculosis cases 
Age and sex 
The age and sex of TB cases is shown in table 11. Those aged between 15-34 accounted for 
600 (69%) notifications. Those aged 35-54 accounted for 192 (22%) cases. Males made up 
450 (52%) notifications.  
Table 11. Age and sex for 873 tuberculosis notifications. 
Age group  Number Percent 
0-14 18 2.1 
15-34 600 68.7 
35-54 192 22.0 
>55 60 6.9 
Total 873 100 
   
Sex   
Female 423 48.5 
Male 450 51.5 
Total  873 100 
Total and percentage in age group does not = 873 or 100% due to random rounding. Correct total is 





District Health Board 
Table 12 shows the distribution of cases by District Health Board (DHB). There were 219 
cases from the Auckland DHB (25%), and 138 (16%) from Counties Manukau DHB. South 
Canterbury, Tairawhiti, West Coast and Whanganui each had less than six notifications of 
TB. 
Table 12. District Health Board of 873 tuberculosis cases. 
District Health Board Number Percent 
Auckland 219 25.1 
Bay of Plenty 36 4.1 
Canterbury 96 11.0 
Capital and Coast 78 8.9 
Counties Manukau 138 15.8 
Hawke's Bay 15 1.7 
Hutt Valley 30 3.4 
Lakes 9 1.0 
Mid-Central 30 3.4 
Nelson Marlborough 15 1.7 
Northland 9 1.0 
South Canterbury <6 <0.7 
Southern 15 1.7 
Tairawhiti <6 <0.7 
Taranaki 9 1.0 
Waikato 51 5.8 
Waitemata 111 12.7 
West Coast <6 <0.7 
Whanganui <6 <0.7 
Total  873 100 
Exact number of cases in District Health Board with <6 cases suppressed. During the study period, 
Southland and Otago merged to form Southern District Health Board. 
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Disease characteristics  
Laboratory confirmation was seen in 774 (89%) people with TB notifications. The basis of 
discovery of TB was ‘attended practitioner’ in 663 (76%) cases. ‘Immigrant screening’ was 
the basis of discovery for 147 (17%) of notifications, ‘contact follow up’ in 18 (2%) and 
‘unknown’ or ‘other’ in 42 (5%) notifications.  
There were 45 (5%) notifications with TB contact within New Zealand. Less than six of these 
cases were documented as part of a known outbreak. Exclusively pulmonary TB accounted 
for 333 cases (38%), exclusively extrapulmonary TB 408 cases (47%), and both pulmonary 
and extrapulmonary TB 126 cases (14%).  
Incidence of tuberculosis according to migrant characteristics 
Age, sex and incidence of tuberculosis 
Migrants between the age of 15-34 had the highest number of TB cases, with 600 cases. The 
incidence of TB in this group was 36 per 100,000 (95% CI: 33-39), (Table 13). The next 
highest group was those aged 35-54 (192 cases, incidence 33 per 100,000, 95% CI: 29-38). 
Those age 0-14 had the lowest number of cases and incidence (18 cases, incidence 4.3 per 
100,000, 95% CI: 2.7-6.8).  
Using the age group 35-54 as a comparator, the rate ratio (RR) for those aged 0-14 was 0.1 
(95% CI: 0.08-0.2). Other age groups did not differ from the comparator group, but the 
numbers of migrants in the oldest (and youngest) age groups were low.   
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The incidence in females was 31 per 100,000 (95% CI: 28-34) and in males 30 (95% CI: 28-




Table 13. Incidence and rate ratio of tuberculosis in long-term migrants to New Zealand according to age and sex. 
Age 
(years) 

















0-14 18 134 421 4.3 2.7-6.8 0.1 0.08-0.2 
15-34 600 1,075 1,677 35.8 33.0-38.7 1.1 0.9-1.3 
35-54 192 292 578 33.2 28.8-38.3 1.0 ref 
³55 60 96 175 34.3 26.6-44.1 1.0 0.8-1.4 
        
Sex  
       
Female 423 763 1,368 30.9 28.1-34.0 1.0 ref 
Male 450 834 1,483 30.3 27.7-33.3 1.0 0.9-1.1 
TB= tuberculosis, ref= reference group 
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Region of origin and incidence of tuberculosis 
South-Central Asia had the highest number of TB cases (459 cases, 53%), and the highest 
incidence (105 per 100,000, 95% CI: 96-115), (Table 14). The next highest number of cases 
and incidence was from South-East Asia (222 notifications, incidence 59 per 100,000, 95% 
CI: 52-68). Sub-Saharan African migrants accounted for 48 cases (25 per 100,000, 95% CI: 
19-33). North East Asian migrants were the second highest group in terms of numbers of 
migrants and person-time at risk yet had the fourth highest incidence (69 cases, 15 per 
100,000, 95% CI: 12-19). There were 54 TB cases from Pacific countries (15 per 100,000, 
95% CI: 12-20). 
High numbers of migrants arrived from Europe (571,599 migrants and 771,777 person-years 
at risk) but this region had low numbers of TB cases and a correspondingly low incidence 
(1.2 per 100,000, 95% CI: 0.6-2.2). There were less than six TB notifications from each of 
North America, Latin America and the Caribbean, and North Africa and the Middle East 
(exact number is suppressed). Using the maximum possible number of five cases, the 
incidence in North America was 3.9 per 100,000 (95% CI: 1.6-9.4), Latin America and 
Caribbean 5.9 (95% CI: 2.5-14), and North Africa and Middle East 11 (95% CI: 5-14).  
Using Europe as a comparator group, the RR for each region is shown. The RR is highest for 
South-Central Asia (90 times the rate in Europe, 95% CI: 47-174), followed by South-East 
Asia (RR 50.7, 95% CI: 26.1-98.8). The RR for Sub-Saharan Africa is 21.6 (95% CI: 10.6-
44.0), North-East Asia 12.6 (95% CI: 6.3-25.3), and the Pacific 13.2 (95% CI: 6.5-26.8). Due 
to suppression, risk ratios for North America, Latin America and the Caribbean, and North 
Africa and the Middle East are calculated using a maximum of five TB notifications from 
these regions. The RR for North America is 3.4 (95% CI: 1.1-10.0), Latin America and the 
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Caribbean 5.1 (95% CI: 1.7-15.1), and North Africa and the Middle East 9.6 (95% CI: 3.2-
28.7)
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Europe 9 572 772 1.2 0.6-2.2 1.00 ref 
Sub-Saharan Africa 48 55 191 25.2 19.0–33.4 21.6 10.6-44.0 
North-East Asia 69 295 469 14.7 11.6-18.6 12.6 6.3-25.3 
South-East Asia 222 174 375 59.2 51.9-67.5 50.7 26.1-98.8 
South-Central Asia 459 177 438 104.8 95.7-114.9 89.9 46.5-173.9 
Pacific  54 119 350 15.4 11.8-20.2 13.2 6.5-26.8 
Data for North America, Latin America and Caribbean, and North Africa and Middle East suppressed and therefore not presented. Ref= reference group 
 58 
 
Country of origin and incidence of tuberculosis in New Zealand 
Incidence for all countries of origin with more than five TB cases is shown in table 15. India 
accounts for 402 notifications (46% of all notifications), with an incidence of 111 per 
100,000 (95% CI: 101-123) in New Zealand. Philippines has the second highest number of 
cases, with 120 (57 per 100,000, 95% CI: 48-69), followed by China (57 cases, 19 per 
100,000, 95% CI: 15-25). These three countries account for 66% of all TB cases in this study. 
All of the top eight countries in terms of case numbers, with the exception of South Africa 
are in Asia, reflecting both high incidence and high migration from this area. There were 
three Pacific Island countries with more than five TB cases. Case numbers for all other 
Pacific countries are suppressed.  
Figure 3 compares the incidence of TB notification in New Zealand against the average 
estimated WHO country incidence rate over the study period. Overall, there is a relationship 
between WHO incidence in country of origin and incidence in New Zealand. In all but two 
countries (Samoa and Papua New Guinea), the incidence in New Zealand is less than the 
incidence in the country of origin. In these countries, New Zealand incidence and country of 
origin incidence are not significantly different as confidence intervals overlap.  
In some countries, the incidence in New Zealand is much lower than the incidence in the 
country of origin. For South Africa, the New Zealand incidence is 12 per 100,000 (95% CI: 
7-18), yet in the country of origin is 872 per 100,000 (95% CI: 632-1153). For Philippines the 
incidence in New Zealand is 57 per 100,000 (95% CI: 48-69), and in the country of origin is 
537 per 100,000 (95% CI: 295-850). Zimbabwe and Cambodia have similar disparities 
between average WHO incidence and New Zealand incidence.  
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Table 15. Incidence of tuberculosis in long-term migrants to New Zealand according to country, for 
countries with 6 or more cases. 








India 402 360,864 111.4 101.0-122.8 
Philippines 120 209,094 57.4 48.0-68.6 
China 57 294,435 19.4 14.9-25.1 
Malaysia 24 51,741 46.4 31.1-69.2 
Myanmar 21 12,429 169.0 110.2-259.1 
Indonesia 21 17,391 120.8 78.7-185.2 
South Africa 18 155,799 11.6 7.3-18.3 
Vietnam  18 24,096 74.7 47.1-118.6 
Pakistan 15 12,933 116.0 69.9-192.4 
Papua New 
Guinea 
15 2,736 548.2 330.5-909.4 
Samoa 15 106,941 14.0 8.5-23.5 
Fiji 12 155,715 7.7 4.4-13.6 
Thailand 12 36,156 33.2 18.8-58.4 
Afghanistan 9 8,124 110.8 57.6-212.9 
Nepal 9 8,565 105.1 54.7-202.0 
Ethiopia 9 3,834 234.7 122.1-451.2 
South Korea 9 95,082 9.5 4.9-18.2 
Cambodia 9 12,885 69.8 36.3-134.2 
Bhutan 6 5,592 107.3 48.2-238.8 
Sri Lanka 6 33,504 17.9 8.0-39.9 






Figure 3. Incidence of tuberculosis in migrants to New Zealand by incidence in country of origin 
according to World Health Organization reported statistics. 
WHO average incidence over ten year period 
(https://www.who.int/tb/country/data/download/en/). Red line represents line of best fit. Only 
countries with 6 or more cases between 1/1/2007 and 31/12/2016 are shown. AF= 
Afghanistan, BT= Bhutan, CN= China, ET= Ethiopia, FJ= Fiji, ID= Indonesia, IN= India, 
KH= Cambodia, KR= South Korea, LK= Sri Lanka, MM= Myanmar, MY= Malaysia, NP= 
Nepal, PG= Papua New Guinea, PH= Philippines, PK= Pakistan, TH= Thailand, VN= 
Vietnam, WS= Samoa, ZA= South Africa, ZW= Zimbabwe 
 
WHO incidence and New Zealand tuberculosis incidence 
Overall, the incidence of TB in New Zealand increased according to WHO estimated 
incidence in the country of origin. The exception to this was seen in very high TB burden 
countries (³350 per 100,000), where the New Zealand incidence was lower than in the 150-
349 per 100,000 group (Table 16).  
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Migrants from countries with a 2016 WHO incidence rate of <40 per 100,000 accounted for 
33 TB notifications, in over 1.1 million person-years of time at risk. The incidence in this 
group was 2.8 per 100,000 person-years (95% CI: 2.0-4.0). The highest incidence was seen in 
those from countries with a WHO incidence of 150-349 per 100,000, at 104 per 100,000 
(95% CI: 95-113).  
Using a WHO incidence of <40 per 100,000 as a comparator, those with WHO incidence of 
40-149 had a RR of 6.2 (95% CI: 4.3-9.1). Migrants from a country with WHO incidence of 
150-349 had a RR of 36.8 (95% CI: 25.9-52.3), and those from a country with incidence 




























<40 33 844 1,173 2.8 2.0-4.0 1.00 ref 
40-149 138 412 787 17.5 14.8-20.7 6.2 4.3-9.1 
150-349 501 198 484 103.5 94.8-113.0 36.8 25.9-52.3 
³350 204 141 406 50.3 43.8-57.7 17.9 12.4-25.8 
WHO = World Health Organization. Ref= reference group. WHO incidence = 2016 WHO estimated TB incidence per 100,000 in country of origin. Data 
sourced from Global Tuberculosis Report 2017, WHO
 63 
To understand the size and potential impact of enhanced screening, such as for LTBI targeted 
according to WHO incidence in country of origin the cumulative percentage of TB cases was 
plotted against the cumulative percentage of migrants in the cohort (Figure 4). Using a WHO 
incidence of >349 per 100,000, 9% of migrants (141,000 people), in whom 23% of TB cases 
were detected, would have been screened. Altering the screening threshold to those coming 
from countries with a WHO incidence of >149 per 100,000, 21% of migrants (340,000 
people) and 80% of TB cases would have been screened. Screening in those coming from 
countries with an incidence of >39 per 100,000 would include 47% of the migrant cohort 
(753,000 people), and 96% of the TB cases.  
 
Figure 4. Proportion of cases of tuberculosis in migrants to New Zealand screened and proportion of 
migrant cohort screened. 




Visa category and incidence of tuberculosis   
Migrants on a student visa had the highest number of TB cases and the highest incidence 
(330 cases, incidence 41 per 100,000, 95% CI: 37-46), (Table 17). Work visas accounted for 
264 notifications (26 per 100,000, 95% CI: 23-29), and resident visas (including permanent 
residents) accounted for 258 notifications (27 per 100,000, 95% CI: 24-30). There were less 
migrants entering on a limited visa, and correspondingly lower numbers of TB cases (21 
cases, 30 per 100,000, 95% CI: 19-46).  
Using resident visas as a comparator group, students had a higher risk of TB (RR 1.5, 95% 
CI: 1.3-1.8). There was no difference in the RR in those with work or limited visas. 
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Table 17. Incidence and rate ratio of tuberculosis in long-term migrants to New Zealand according to visa type. 


















Resident 258 447 969 26.6 23.6-30.1 1.00 ref 
Limited 21 84 71 29.7 19.4-45.5 1.1 0.7-1.7 
Student 330 362 797 41.4 37.1-46.1 1.5 1.3-1.8 
Work  264 704 1,014 26.0 23.1-29.4 1.0 0.8-1.2 
Ref= reference group 
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Multivariate analysis  
Three models were used for the multivariate analysis. The first shows adjusted rates by visa 
type, to account for potential age confounding. Subsequent analysis incorporated age, sex and 
visa type into models using either region of origin, or WHO incidence.  
Age and visa type 
When adjusted for age, migrants with a student visa have an adjusted RR of 1.3 (95% CI: 
1.1-1.6) compared with those with a resident visa (Table 18). This is lower than the RR of 1.5 
seen in the univariate analysis, indicating that age is confounding this association. Similar 
confounding is seen in all visa categories where risk ratios change by more than 10% 
following adjustment for age. Those with work visas have a lower adjusted RR of TB 
compared with resident visas (RR 0.7, 95% CI: 0.6-0.9). 
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Table 18. Univariate and multivariate analysis of age and visa type and tuberculosis incidence. 
Variable  Incidence per 
100,000 (95% CI) 
Unadjusted 
RR (95% CI) 




   
 
Resident 26.6 (23.6-30.1) 1.0 (ref) 1.0 (ref)  
Limited 29.7 (19.4-45.5) 1.1 (0.7-1.7) 0.8 (0.5-1.3) 0.4 
Student 41.4 (37.1-46.1) 1.5 (1.3-1.8) 1.3 (1.1-1.6) <0.005 
Work 26.0 (23.1-29.4) 1.0 (0.8-1.2) 0.7 (0.6-0.9) <0.005 
Age group  
   
 
0-4 
4.3 (2.7-6.8) 0.1 (0.08-0.2) 
0.1 (0.05-0.3) <0.005 
5-14 0.3 (0.2-0.4) <0.005 
15-34 35.8 (33.0-38.7) 1.1 (0.9-1.3) 1.3 (1.1-1.6) <0.005 
35-54 33.2 (28.8-38.3) 1.0 (ref) 1.0 (ref)  
³55 34.3 (26.6-44.1) 1.0 (0.8-1.4) 1.0 (0.7-1.4) 0.9 
CI= confidence interval, RR= Rate ratio, ref= reference group. Multivariate analysis with visa type 
and age adjusted. Age group reported as 0-14 years in the univariate analysis to avoid suppression of 
the number of notifications in the 0-4 and 5-14 groups. Age groups reported as 0-4 and 5-14 for the 




Region of origin 
When co-variates of region, visa type, age and sex were adjusted for, region of origin is the 
variable most strongly associated with TB in migrants to New Zealand (Table 19). Compared 
with Europe, the highest adjusted RR is in migrants from South-Central Asia, with an 
adjusted RR of 95.6 (95% CI: 49.2-185.6). The next highest group is from South-East Asia 
(adjusted RR 57.5, 95% CI: 29.5-112.1), followed by Sub-Saharan Africa (adjusted RR 25.1, 
95% CI: 12.3-51.2), Pacific (adjusted RR 14.7, 95% CI: 7.2-29.9), North-East Asia (adjusted 
RR 12.8, 95% CI: 6.3-25.6) and North Africa and Middle East (adjusted RR 10.7, 95% CI: 
3.6-32.1). There was no statistically significant increase in the TB risk in migrants from 
North America, and Latin America and Caribbean. Changes in unadjusted and adjusted risk 
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ratios suggest that univariate results are impacted by confounding. Confounding impacts risk 
in both directions, with some regions (North America, Latin America and Caribbean) having 
a lower adjusted RR in the multivariate model, and other regions (Sub-Saharan Africa and 
South East Asia) having a higher adjusted RR.  
Student visa holders had a small, but statistically significant reduction in TB risk in this 
model when compared with residents (adjusted RR 0.8, 95% CI: 0.7-0.98). Limited and work 
visa holders showed no difference in TB risk. On univariate analysis, a student visa appears 
to be associated with 50% increase in TB risk, yet when confounding is accounted for in the 
multivariate analysis, there is actually a 20% reduction in risk (although the confidence 
interval is very close to the null value of 1.00).  
When adjusted for region, visa and sex, young age showed a lower risk of TB compared with 
the 35-54 age group. Reduced risk was seen in those aged 0-4 (adjusted RR 0.1, 95% CI: 
0.04-0.3) and 5-15 (adjusted RR 0.3, 95% CI: 0.2-0.5). Higher risk was seen in the age group 
15-34 (adjusted RR 1.2, 95% CI: 1.02-1.5). No significant difference was seen in those aged 
55 or over. Some confounding is present in the older age groups where an increase from 
univariate to adjusted RR is seen.   
Male sex showed a lower risk of TB than females in the multivariate analysis, with an 
adjusted RR of 0.8 (95% CI: 0.7-0.9). No difference was seen in the univariate analysis, 
likely due to the effect of confounding of other studied variables. 
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Table 19. Univariate and multivariate analysis of region, visa, age, sex and tuberculosis incidence. 
Variable  Incidence per 







   
 
Europe 1.2 (0.6-2.2) 1.0 (ref) 1.0 (ref)  
North America S 3.4 (1.1-10.0) 2.0 (0.5-7.4) 0.3 
Latin America and 
Caribbean 
S 5.1 (1.7-15.1) 3.0 (0.8-11.0) 0.1 
North Africa and 
Middle East 
S 9.6 (3.2-28.7) 10.7 (3.6-32.1) <0.005 
Sub-Saharan Africa 25.2 (19.0-33.4) 21.6 (10.6-44.0) 25.1 (12.3-51.2) <0.005 
North-East Asia 14.7 (11.6-18.6) 12.6 (6.3-25.3) 12.8 (6.3-25.6) <0.005 
South-East Asia 59.2 (51.9-67.5) 50.7 (26.1-98.8) 57.5 (29.5-112.1) <0.005 
South-Central Asia 104.8 (95.7-114.9) 89.9 (46.5-173.9) 95.6 (49.2-185.6) <0.005 
Pacific  15.4 (11.8-20.2) 13.2 (6.5-26.8) 14.7 (7.2-29.9) <0.005 
Visa Type 
   
 
Resident 26.6 (23.6-30.1) 1.0 (ref) 1.0 (ref)  
Limited 29.7 (19.4-45.5) 1.1 (0.7-1.7) 0.7 (0.5-1.2) 0.2 
Student 41.4 (37.1-46.1) 1.5 (1.3-1.8) 0.8 (0.7-0.98) 0.03 
Work 26.0 (23.1-29.4) 1.0 (0.8-1.2) 0.9 (0.8-1.1) 0.4 
Age Group  
   
 
0-4 
4.3 (2.7-6.8) 0.1 (0.9-1.3) 
0.1 (0.04-0.3) <0.005 
5-14 0.3 (0.2-0.5) <0.005 
15-34 35.8 (33.0-38.7) 1.1 (0.9-1.3) 1.2 (1.02-1.5) 0.03 
35-54 33.2 (28.8-38.3) 1.0 (ref) 1.0 (ref)  
³55 34.3 (26.6-44.1) 1.0 (0.8-1.4) 1.2 (0.9-1.7) 0.2 
Sex  
   
 
Female 30.9 (28.1-34.0) 1.0 (ref) 1.0 (ref)  
Male 30.3 (27.7-33.3) 1.0 (0.9-1.1) 0.8 (0.7-0.9) 0.006 
S= suppressed, CI= confidence interval, RR= Rate ratio, ref= reference group. Multivariate analysis 
with region of origin, visa, age and sex adjusted. Age group reported as 0-14 years in the univariate 
analysis to avoid suppression of the number of notifications in the 0-4 and 5-14 groups. Age groups 
reported as 0-4 and 5-14 for the multivariate analysis.  
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WHO incidence 
When WHO incidence, visa type, age and sex were mutually adjusted, WHO incidence is the 
variable most strongly associated with TB in migrants to New Zealand (Table 20). However, 
this association is not linear. Compared with the lowest WHO incidence band of <40 per 
100,000, those from countries with a WHO incidence of 150-349 per 100,000 had an adjusted 
RR of 36.1 (95% CI: 25.4-51.4). Those from countries with a WHO incidence ³350 per 
100,000 had a higher adjusted RR compared to the lowest incidence group, but the point 
estimate was lower than those from countries with WHO incidence of 150-349 per 100,000, 
with an adjusted RR of 19.6 (95% CI: 13.6-28.3). Changes between univariate and 
multivariate rate ratios are small, suggesting that confounding from age, sex and visa 
category does not impact on TB risk by WHO incidence category.  
When compared with resident visas, there was no difference in TB risk among student, work 
or limited visa holders. The risk of TB in those with a student visa appears to be 50% higher 
in univariate analysis yet there is no significant difference in this multivariate model after 
confounding is accounted for.  
Age and sex showed similar results when adjusted in models containing region of origin, or 
WHO incidence rate. Those aged 0-4 (adjusted RR 0.1, 95% CI: 0.05-0.4) and 5-14 (adjusted 
RR 0.3, 95% CI: 0.2-0.5) had lower risk of TB compared with those aged 35-54. Those aged 
15-34 had higher risk (adjusted RR 1.3, 95% CI: 1.1-1.6). Males had a lower risk than 
females (adjusted RR 0.8, 95% CI: 0.7-0.9) on multivariate analysis, but not on univariate 
analysis. 
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Table 20. Univariate and multivariate analysis of World Health Organization incidence, visa, age, 
sex and tuberculosis incidence. 
Variable  Incidence per 








   
 
<40 2.8 (2.0-4.0) 1.0 (ref) 1.0 (ref)  
40-149 17.5 (14.8-20.7) 6.2 (4.3-9.1) 6.1 (4.2-9.0) <0.005 
150-349 103.5 (94.8-113.0) 36.8 (25.9-52.3) 36.1 (25.4-51.4) <0.005 
³350 50.3 (43.8-57.7) 17.9 (12.4-25.8) 19.6 (13.6-28.3) <0.005 
Visa Type 
   
 
Resident 26.6 (23.6-30.1) 1.0 (ref) 1.0 (ref)  
Limited 29.7 (19.4-45.5) 1.1 (0.7-1.7) 0.8 (0.5-1.3) 0.4 
Student 41.4 (37.1-46.1) 1.5 (1.3-1.8) 0.9 (0.7-1.1) 0.2 
Work 26.0 (23.1-29.4) 1.0 (0.8-1.2) 1.0 (0.8-1.2) 0.7 
Age Group  
   
 
0-4 
4.3(2.7-6.8) 0.1 (0.9-1.3) 
0.1 (0.05-0.4) <0.005 
5-14 0.3 (0.2-0.5) <0.005 
15-34 35.8 (33.0-38.7) 1.1 (0.9-1.3) 1.3 (1.1-1.6) 0.01 
35-54 33.2 (28.8-38.3) 1.0 (ref) 1.0 (ref)  
³55 34.3 (26.6-44.1) 1.0 (0.8-1.4) 1.2 (0.9-1.7) 0.2 
Sex  
   
 
Female 30.9 (28.1-34.0) 1.0 (ref) 1.0 (ref)  
Male 30.3 (27.7-33.3) 1.0 (0.9-1.1) 0.8 (0.7-0.9) 0.006 
CI = confidence interval, RR = Rate ratio, ref= reference group, WHO = World Health Organization. 
WHO incidence = 2016 WHO estimated TB incidence per 100,000 in country of origin. Data sourced 
from Global Tuberculosis Report 2017 – WHO. Multivariate analysis with WHO incidence band, 
visa, age and sex adjusted. Age group reported as 0-14 years in the univariate analysis to avoid 
suppression of the number of notifications in the 0-4 and 5-14 groups. Age groups reported as 0-4 and 
5-14 for the multivariate analysis.  
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Chapter 6. Integrated Data Infrastructure cohort study - 
discussion  
A cohort of long-term migrants to New Zealand was constructed and followed up to ten years 
post arrival in New Zealand. TB notifications were linked to this dataset. Country of origin 
incidence was strongly associated with TB risk. Overall risk of TB in New Zealand increased 
with increasing incidence in the country of origin, however not in the highest incidence 
category. Risk was also associated with the world region of origin, as in general, countries 
within a world region will have similarly high, or low TB incidence. Risk of TB was also 
highest for migrants who arrived at an age between 15 to 34 years and for females, compared 
to males. There was no significant difference in risk according to a migrants’ visa category.    
The incidence rates were different by world region, with the highest rates seen in migrants 
from South-Central Asia and South-East Asia. TB incidence in those migrating from Europe 
is low, being less than the overall New Zealand rate (6.3 per 100,000), and less than the rate 
for non-foreign born New Zealanders (1.9 per 100,000) (2). Over one third of migrants in this 
study are from Europe. The incidence in those from North America, Latin America and 
Caribbean, and North America and Middle East could not be presented due to Statistics New 
Zealand suppression rules, however maximum possible incidence rates are also low.  
Regional incidence is consistent with previously published incidence in official reports of 
surveillance data (2). The incidence by region in this study should arguably be more accurate 
than that produced in current reports published by ESR, however there is remarkable 
agreement between the two. Incidence per 100,000 in South-Central Asia (ESR 107, New 
Home study 105), South-East Asia (ESR 54, New Home 59), North-East Asia (ESR 18, New 
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Home 15) and Europe (ESR 1.3, New Home 1.2) are all very similar. My analysis differs 
from that in official reports with respect to the assignment of country of origin and the 
population included. ESR use birth country as reported by notifying doctor whereas this 
study used nationality based on arrival information. Nationality likely reflects TB risk more 
accurately than country of birth as it is assumed that a migrant has spent considerable and 
recent time in that country prior to migration. ESR reports analyse all foreign-born cases, 
including those who migrated many years previously and including visitors. The denominator 
population in ESR analyses is the resident population reporting that nationality from census 
data. In contrast the New Home study includes migrants who arrived within ten years. In 
general rates of TB in migrants to low prevalence countries decline as time from migration 
increases, so the longer follow up time in the ESR analysis would be expected to result in 
lower rates of TB than in the present study. Similarities of the calculated incidences may 
result from additional cases (visitors) counting towards ESR numerator or because TB risk in 
migrants does not decrease over time as expected, perhaps because of increasing comorbidity 
increasing risk of reactivation.  
In multivariate analysis, region of origin is strongly associated with TB risk once age, sex and 
visa category are adjusted for. Compared to the lowest incidence region Europe, the highest 
rate of TB is seen in those from South-Central Asia, followed by South East Asia and Sub-
Saharan Africa. Confidence intervals are wide but still show that these groups are at 
substantially higher risk than Europe.  
The incidence of TB in New Zealand increased as WHO incidence in the country of origin 
increased, however in all WHO incidence bands, the incidence in migrants to New Zealand is 
less than the lower limit of WHO incidence. Similar trends have been seen in cohort studies 
of migrants to the United Kingdom and Canada (44,83). The exception to this is in migrants 
 74 
from countries with the highest WHO incidence of ³350 per 100,000, who have a lower New 
Zealand incidence than those from countries with a WHO incidence of 150-349 per 100,000. 
Multivariate analysis shows that this trend remains when age, sex and visa category are 
adjusted for. A similar finding was seen in the United Kingdom (82). A possible reason for 
this in my study is the influence of migration from South Africa and Philippines. These 
countries have very high WHO incidence (781 and 554 per 100,000 respectively), yet 
significantly lower New Zealand incidence. There is high migration from these two countries, 
which accounts for 90% of the total person-time for countries with WHO incidence >349 per 
100,000. Collectively these findings likely reflect selection factors that result in a lower risk 
cohort of individuals migrating than remaining in high prevalence countries. This is likely to 
occur overall, given the financial resources required to migrate to New Zealand. In certain 
countries specific selection factors may arise. For example migrants from South Africa are 
possibly of high socioeconomic status and low risk of TB despite living in the highest 
incidence country in the world. They are possibly less likely to have TB infection or have 
risks of reactivation compared with their non-migrant counterparts. In the case of the 
Philippines the high proportion of migrants working in health may mean that they have LTBI 
screening and treatment as part of pre-employment occupational health procedures.  
Numbers of New Zealand TB cases are a function of both the number of migrants, and the 
incidence of TB in migrant-donating countries. In 21 countries with six or more TB cases, 
New Zealand incidence is positively correlated with incidence in the country of origin, 
although for most countries New Zealand incidence is lower than incidence in the country of 
origin. A similar finding is seen in migrants to Australia and United States (7,114). For some 
countries, the overall number of cases and migrants are low meaning incidence estimates can 
lack precision. Also, country level rates were not modelled so confounding may be present. 
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The lower incidence of TB in New Zealand compared to country of origin is likely to reflect 
the selection of a low risk cohort for migration and, over time, attenuating risk following 
residence in a low transmission environment. This is seen in the United States, where risk 
reduces by 65% in the second year after arrival (114). The selection factors include 
immigration screening itself that excludes people with incident TB and prevents migration in 
those diagnosed offshore. As discussed above, policy and other factors mean that migrants 
are often a high socioeconomic, low risk subset of the country from which they are drawn.  
The lowest risk of TB by age in the multivariate analysis was seen in those aged 0-4 and 5-14 
years. A small increase in risk was seen in those aged 15-34, when compared with those aged 
35-54. The proportions of TB cases by age are similar to the proportions in each age bracket 
in the overall cohort, which is made up predominantly of ‘working age’ migrants, from 15-54 
years. The lower incidence of TB in ages 0-14 is similar to overall New Zealand incidence 
(2), and incidence in migrants to the United States (114). Children may be at lower risk of TB 
in this study because of the natural history of disease, with those between the age of 2-10 
years being less likely to develop overt TB symptoms following primary infection (115). 
Additionally, if children had migrated to New Zealand some years ago, they may be at less 
risk of infection due to less transmission within the community. This study did not analyse 
data on time since arrival, so is unable to say whether the low incidence in children relates to 
a lower risk of transmission within New Zealand. This study found a higher risk in young 
adults, which has been previously documented in the general literature (115). An increased 
rate in older age groups was not found, which is different to a study of migrants in Victoria, 
Australia (116). This study found a bimodal age distribution of incidence, with peaks in the 
20-29, and >65 year age groups. This may be due to the longer follow up time of 35 years, 
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allowing more time for the reactivation of LTBI, or comorbidities that promote LTBI 
reactivation such as diabetes, to develop. 
Males had a lower risk of TB compared with females in multivariate analysis. This contrasts 
with New Zealand 2016 data, where males had a higher notification rate than females (2). 
Globally, it is estimated that 65% of cases of TB are in males (1). The reasons for differences 
in sex related risk in this study are unclear. Pregnancy and the postpartum period increase the 
risk of reactivation of LTBI (117), but it is unlikely that this would occur in this study to such 
a level as to cause significant differences.  
Type of visa was not strongly correlated with TB. In the multivariate analysis adjusting for 
age, sex and region of origin, but not in the model adjusting for WHO incidence, student 
visas had a slightly lower risk of TB. When adjusted for age, sex and WHO incidence, there 
was no difference in risk. In both models, work and limited visas had the same rate as those 
on resident visas. There is significant confounding impacting on risk for those on student 
visas, with large changes in rate ratios seen from univariate analysis to multivariate analysis 
where confounders are adjusted for. One study in the United Kingdom found ‘settlement and 
dependant’ visas to be associated with increased risk of TB (82). Another study in the same 
country found this group to be at lower risk, and ‘family reunification’ visas to have the 
highest rate ratio (44). Both of these groups would fall under the ‘resident’ visa category in 
New Zealand. Differing migration patterns to New Zealand and the United Kingdom likely 
account for these differences. There is little inherent TB risk in different visa categories that 
is not likely to be accounted for by confounders such as age, sex and region of origin. 
Migrants from countries with a WHO incidence less than 40 per 100,000 had a low incidence 
of TB in New Zealand. Just over half of migrants to New Zealand come from countries in 
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this incidence band. Currently radiological screening is required in all migrants staying for 
more than twelve months, or more than six months if coming from a high incidence country, 
and would include the majority of migrants in this cohort. In some cases screening will be 
performed off-shore, therefore this rate needs to be understood as the incidence in a 
population that is, at least in part, screened. It is clear that there is very little scope to further 
reduce the risk of TB in this group through adding LTBI screening to the existing screening. 
This study cannot assess if off-shore radiological screening of this group is worthwhile, as 
cases diagnosed off shore would not be notified in New Zealand.   
TB cases identified by onshore screening were included in this study. Based on notification 
data they comprised 17% of the included cases. This is consistent with ESR reports showing 
69% of TB cases in migrants occur more than two years after arrival and therefore are 
unlikely to be diagnosed through immigration screening (2). This pattern is consistent with 
other low-incidence countries that have high rates of migrant-related TB (33). It is likely that 
LTBI screening is necessary to achieve any substantial reduction in TB incidence in NZ. This 
study did not assess time from arrival to diagnosis which would further assist in 
understanding how many of the cases were prevalent cases diagnosed at radiological 
screening compared to cases of LTBI reactivation.   
Extrapulmonary TB accounted for just under half of all cases in this study. In non-foreign 
born cases in New Zealand, pulmonary TB predominates, but in foreign born cases, 
approximately half of TB is extrapulmonary (2). Data from England shows a similar trend 
(39). This likely reflects both success, and limitations in radiological screening – cases of 
pulmonary TB in migrants are detected off-shore and treated prior to migration, thus 
selecting out these cases. Those with extrapulmonary TB will usually not be detected by 
screening and thus extrapulmonary involvement is seen in higher proportions of migrants. 
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Time from arrival to diagnosis of extrapulmonary disease would distinguish those cases that 
had disease at the time of migration, from those who developed extrapulmonary disease as a 
result of reactivation of LTBI. This would have implications for future potential LTBI 
screening.     
A limitation in this study is the potential bias introduced by migrants with a prior stay in New 
Zealand. Migration pathways are not always straightforward, with many migrants traveling to 
New Zealand (often as visitors) prior to their ‘arrival’ as defined in this study. I considered 
excluding migrants with a significant stay in New Zealand prior to migration, as they are at 
lower risk of TB if they have spent a significant amount of time in a low transmission 
environment before migrating. This would have led to a significant proportion of the cohort 
excluded, and thus exclusions based on prior stay in New Zealand were not used for the final 
analysis.  
Another limitation is that visitors were excluded. Health and migration data for visitors are 
unable to be linked in this study because visitors are not part of the IDI spine. New Zealand 
received almost 3.8 million visitors in the year ending July 2018, with 83% staying for three 
weeks or less (118). TB is a slowly progressive disease and it is thought that short term 
visitors are unlikely to present with symptoms in New Zealand. Only 4% of TB notifications 
included those who did not have dual nationality and arrived on a visa not included in this 
study. This study is unable to further assess the visa status of these arrivals but acknowledge 
that many of these could be visitors. Visitor visas of up to nine months may be granted and 
are subject to the same medical requirements as other migrants. The small numbers of longer-
term visitors would have similar risks for TB as other migrants staying for a similar duration 
yet are not included in this study. Without detailed denominator data the impact on incidence 
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is unclear. The findings of this study cannot be generalised to visitors or other excluded visas, 
and further assessment to assess their risk of TB could be undertaken.  
A further limitation is that 84 notifications (3%) had no movement data in the IDI yet arrived 
in New Zealand during the study period according to ESR notification data. These people are 
likely unable to be linked to the IDI spine. Non-linkage may occur because an individual is 
not present in the IDI spine (i.e. not born in, or paying tax in New Zealand, and did not arrive 
on a visa allowing work, study or residence), or may be a result of linkage errors. Incomplete 
data entry and false positive or negative matches in the linking process are possible. I am 
unable to further clarify the reasons for these exclusions and acknowledge that some TB 
cases may have met study inclusion criteria yet were not linked due to Statistics New Zealand 
linkage errors. Linking errors are possibly increased in those of non-European or North 
American ethnicity, due to data entry errors or spelling errors with less familiar names, or due 
to the Statistics New Zealand Soundex name matching algorithm being based on English 
pronunciation, although there are no data to confirm this. This would be a source of bias and 
would result in this study underestimating TB incidence and may impact different 
nationalities differently. The magnitude of this is likely to be small due to the small number 
of cases excluded. 
Further limitations are that the study cannot accurately identify who has been infected in New 
Zealand, although a small number had documented contact with a TB case in New Zealand. 
Other groups, such as overstayers, will not be identified in this study. This study has not 
assessed TB cases in the context of their time from arrival to notification. This knowledge 
would allow us to further consider the impact of LTBI reactivation in migrants and the 
implications for LTBI screening in high risk migrant groups.  
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The implications of this study and recommendations for further research are discussed with 
reference to the following audit of migration screening records in Chapter 11.  
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Chapter 7. Literature review on tuberculosis case definitions 
Introduction  
This chapter is a focused literature review used to develop the definitions used in the audit of 
migration screening records.  
Purpose 
The immigration health screening process diagnoses TB in some, but others are missed for a 
variety of reasons. This may be because of misdiagnosis or other programmatic errors, or 
because TB was not present or not clinically detectable at the time of screening and 
developed subsequently. In this latter category some may belong to the higher risk group with 
x-ray changes targeted for post arrival surveillance in other countries, or others may have 
LTBI that is not diagnosed by radiological screening. Finally, the migrant may not have 
LTBI but acquired infection in New Zealand. To assess the quality of New Zealand’s current 
migrant TB screening programme, and to identify further opportunities for prevention, it is 
necessary to assess the frequency of these different scenarios among migrants who develop 
TB. To this end a focused literature review was conducted to identify case definitions for 
each of these states that could be applied to immigration health assessment records. These 
definitions for active TB at the time of screening, inactive TB, early TB, LTBI and 
uninfected at the time of screening (with likely infection in New Zealand) will be applied in 
chapter 8 for the audit of migration screening records.    
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Relevant literature was identified from a PubMed search, using key terms tuberculosis, 
migrant, migration, immigrant, and immigration. Only articles relating to migrant related TB 
in OECD countries were selected. No date restriction was applied.  
Active tuberculosis at the time of screening 
Active TB at the time of screening is referred to as “active, imported TB”, “active prevalent 
TB, or “TB on arrival”, although this latter term obscures the difference between time of 
arrival and time of screening, which can be several months or years. Table 21 summarises 
studies that define prevalent TB. These studies either describe risk factors for TB in migrants 
or analyse the effectiveness of screening. Most define imported, or prevalent, cases as 
occurring within three to six months after migration, the majority being six months.  
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Table 21. Studies of tuberculosis in migrants that define prevalent, or active tuberculosis at arrival 
Study population, (reference) Study design  Prevalent case definition 
(months = time from 
“arrival” to diagnosis) 
Migrants to UK with negative pre-
entry screening (44) 
Cohort study 3 months 
Migrants to USA (119) Cohort study 6 months  
Migrants to Netherlands (120) Cohort study  6 months 
Migrants to USA (121) Cohort study 6 months 
Migrants to Netherlands (122) Cohort study Chest x-ray abnormalities and 
diagnosis within 6 months 
Migrants to Netherlands (123) Cohort study 6 months 
Filipino migrants to USA (124) Cohort study Chest x-ray abnormalities and 
diagnosis within 6 months 
UK= United Kingdom, USA= United States of America 
Inactive tuberculosis  
This state is not well defined in the migration literature. In general TB literature, inactive TB 
refers to chest x-ray findings of fibronodular opacities or scarring, usually in the upper zones 
of the lungs and in the absence of parenchymal infiltrates. These findings suggest healed 
infection, either due to treatment or from spontaneous resolution (125) and are associated 
with a high rate of incident TB as presumably viable bacilli remain in some of these patients 
(89). Some authors also require immunological evidence of TB infection (i.e. a positive 
IGRA or TST) to make the diagnosis (89,126).  
In an Australian case control study, Linh et al found those with either apical fibro-nodular 
disease or multiple non-calcified nodules, or probable previous pulmonary TB (defined as 
fibrosis, nodules or calcified nodules in upper or mid lung zones) had respectively five and 
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seven times greater odds for a subsequent TB diagnosis when compared to controls (127). An 
Israeli study of Somali migrants found that those with ‘old, healed TB’ – defined as hilar or 
upper lobe nodules, apical fibrosis or fibrotic scar, granuloma, pleural thickening, radiologist 
comment ‘old TB’, and active TB ruled out – had ten times the rate of developing active TB 
in the first year compared with immigrants who had a normal chest x-ray (128). 
In a study of Filipino migrants to the United States, the term reactivation of inactive TB is 
applied to any case of TB diagnosed more than six months after arrival in an immigrant with 
an abnormal x-ray (124). 
Early tuberculosis 
A variety of terms are used to describe early states in the progression of latent to 
symptomatic active TB. In the above mentioned study by Linh et al, participants who were 
culture negative but had parenchymal disease with or without cavities, and parenchymal 
infiltrate typical for TB (as distinct from fibrotic changes) had 14 and 15 times the odds of 
progressing to TB in cases when compared to controls (127). This suggests infiltrates on 
chest x-ray may be present when the number of replicating bacilli are too low to be detected 
by culture and before symptoms are present.  
An alternative term, sub-clinical TB is used to describe asymptomatic but culture positive 
cases (129,130). In other literature, sub-clinical TB is used in those who are 
immunocompromised, and incipient TB used for those who are immunocompetent, 
asymptomatic yet with x-ray abnormalities (131). 
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Latent tuberculosis 
When LTBI progresses to active TB it is called reactivation TB. TB in migrants to low 
prevalence countries occurring distant from the time of arrival can be considered reactivation 
TB, because the counterfactual scenario, that infection occurred in the new low prevalence 
setting is very unlikely. Walter et al define reactivation of LTBI in migrants as TB occurring 
in a migrant with a normal preimmigration examination and radiograph (124). Thus LTBI at 
the time of immigration assessment can be inferred in a person with no clinical evidence of 
active TB at the time of screening, even if specific tests for LTBI were not done. Most other 
literature defines LTBI based on positive immunological tests, which are not performed 
routinely in migrants to New Zealand.  
Without immunological tests or epidemiological links to a TB case, differentiating 
reactivation of LTBI from new infection after migration is not possible. Most migrants 
diagnosed with TB in a low transmission setting would be expected to have LTBI 
reactivation, unless there was clear evidence (such as known contact with a case or clustered 
TB strains) that infection was acquired.  
Summary 
Based on the preceding literature review, case definitions were written for the likely TB 
status of the case at the time of screening. Definitions are based on retrospective examination 
of clinical data, with a subsequently diagnosed TB case obviously not available for re-
examination. Immunological tests for LTBI are not performed at screening, the diagnostic 
process for TB is not always simple or clear, and the spectrum of latent, early and active TB 
is arbitrary and x-ray findings in TB are subjective. Thus, definitions devised for this study 
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will not be perfect, and their performance when applied to immigration screening records will 
be evaluated in addition to screening itself.  
These definitions are provided in the audit of migration records methods, chapter 8. I did not 




Chapter 8: Audit of migration screening records - methods 
Introduction  
New Zealand’s migrant TB screening programme has not been formally evaluated against 
health outcomes. This second study is an audit of the immigration health records of migrants 
with TB to assess and identify possible gaps in the current screening programme. To this end 
I have analysed the immigration health screening records, radiology results and specialist 
letters of migrants subsequently diagnosed with TB.  
Objective  
To assess if TB was identified at the time of Immigration New Zealand screening and if not, 
could it have been. 
Study design 
This is a clinical audit of the screening and evaluation of migrants who developed TB after 
their INZ health assessment. TB notifications from ESR were linked to the immigration 
health screening (IHS) records which were audited.  
Setting 
The study includes all TB cases notified in New Zealand between 01/02/2015 and 
31/01/2018. This timeframe corresponds to the beginning of INZ screening medical 
assessments being recorded electronically. 
 88 
Description of dataset 
TB cases (notifications) were sourced from ESR records, as in the IDI cohort study. TB 
notifications in the study period were assigned a unique identifier and matched to INZ health 
screening records by name and date of birth. Notified cases with a screening record were 
included in the dataset. Case demographics, disease site, basis of diagnosis, outbreak details 
and contact history, onset date, birth country and arrival details were obtained from the 
notification data. Medical examination summary data, x-ray reports and where relevant 
specialist letters and further investigation findings were obtained from the immigration 
screening record.  
Participants 
Cases were included if they were notified with TB after an immigration screening medical 
application during the study period.  
Variables 
Age and sex were collected from notification data. Birth country (not nationality, which is 
not recorded by INZ) was defined per IHS data and grouped into regions as per the cohort 
study. The date of IHS was defined as the date of the medical examination, or if only a 
radiological examination was performed, the date of submission of the x-ray. The location of 
the medical examination was defined as onshore (in New Zealand) or offshore (any other 
country). Clinical details including past TB treatment, contact with a TB case, other medical 
conditions and blood test results were obtained from INZ records. Disease characteristics 
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including site of TB, laboratory confirmation and cavitation were obtained from notification 
data.  
Definitions 
The following definitions are either used by ESR or INZ, or developed specifically for this 
study by the researchers. 
ESR and INZ definitions 
TB cases: Either confirmed or probable cases. A confirmed case of TB in New Zealand is 
defined as a clinically compatible illness with laboratory confirmation by any one of: positive 
culture of M. tuberculosis, positive microscopic examination for acid-fast bacilli, positive M. 
tuberculosis nucleic acid or positive histology. A probable case is not laboratory confirmed, 
but has signs and symptoms compatible with active TB and full anti-tuberculosis treatment 
has been commenced by a clinician (19). 
Disease classification: As defined in the New Zealand Communicable Disease Control 
Manual, a new case is active TB in a person never treated for TB before, or who has disease 
from a new genotype. Relapse or reactivation occurs in a person with active TB following a 
period of non-infectivity or quiescence after full, partial or no treatment (19). Reactivation in 
this context reflects a second episode of active TB and does not refer to reactivation of LTBI. 
Laboratory confirmed case: From ESR notification data. Laboratory confirmation requires 
one of positive culture, microscopy, molecular tests or histology (19).  
 90 
Disease site: From ESR notification data. Defined as pulmonary (involving lung 
parenchyma) or extrapulmonary (any other body site) or pulmonary and extrapulmonary 
(both sites affected).  
Basis of discovery: From ESR notification data. Either ‘immigration screening’ or ‘attended 
practitioner’. The latter category indicates symptomatic disease requiring the case to seek 
medical assessment.  
Sputum result: From ESR notification data. Refers to any positive sputum sample, from 
either smear, culture or polymerase chain reaction (PCR). This relates to sputum testing 
performed as a result of the immigration medical / x-ray findings. 
Visa category: From INZ records. Visa type that the medical application relates to.  
Definitions and variables developed by researchers  
Time from screening to notification: Time from IHS screening to notification of TB.  
X-ray findings: X-ray reports were categorised into groups of based on keywords: lung 
parenchymal abnormalities such as cavitation, consolidation, infiltrate, patchy lesion, 
nodules, fibrosis etc; hilar or mediastinal abnormalities or mass; isolated pleural 
abnormalities; other mass or opacity not coded in aforementioned categories; normal x-ray; 
x-ray not performed (unable to ascertain whether x-ray not performed, performed before 
study period or missing data). The keywords were identified from the radiology reports, and 
are the reporting radiologist’s interpretation of the x-ray, thus are not further defined here. 
‘Evidence of TB’ is also included in x-ray reports. This is a binary question which can only 
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be answered ‘yes’ or ‘no’. This is the reporting radiologist’s interpretation and thus I am 
unable to define what exactly what features constitute ‘evidence of TB’.  
Number of x-ray abnormalities: Cumulative keyword categories on x-ray report.  
X-ray normal or abnormal: Used in the second radiologist’s re-read of x-rays. Any one 
abnormality based on the above keywords rendered an x-ray abnormal.  
X-ray interval: Time from x-ray date to IHS submission.  
Likely TB status of the case at time of IHS: Based on the focused literature review discussed 
in chapter 7, I assigned definitions to TB cases based on the likely status of the case at the 
time of IHS.  
- Active TB: TB notified within 6 months of the IHS, regardless of x-ray findings. 
- Inactive TB: TB notified >6months after screening and the IHS x-ray was reported as 
“old TB”, “healed TB with fibrotic or fibronodular change” and microbiological tests 
were negative or not performed. 
- Early TB: TB notified >6 months after screening and the IHS x-ray showed 
parenchymal changes which could be consistent with TB, with no features of inactive 
TB, and microbiological tests were negative or not performed.  
- LTBI: TB notified >6 months after screening with either normal, or no x-ray 
performed.  
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- Likely uninfected: TB notified >6 months after screening with either normal, or no x-
ray performed and infection in New Zealand is possible because the case is linked to 
another New Zealand TB case.  
Analysis 
For each TB case, the most recent, prior IHS report was assessed. This was either a full 
medical application, or a stand-alone chest x-ray report. I reviewed summary data from the 
medical examination, x-ray findings, specialist reports and further investigations and 
classified cases as being likely to be diagnosed as a result of the immigration screening as 
follows: 
- Diagnosed by IHS: a specialist review initiated by INZ resulted in investigations that 
diagnosed TB within six months.  
- Diagnosed by IHS: if there were no specialist letters, and the notification data 
recorded the ‘Basis of discovery’ as ‘immigrant screening’, the time from x-ray to 
notification was less than three months, and the case was pulmonary or sputum 
positive TB. 
- Likely diagnosed by IHS: if there were no specialist letters, and the notification data 
recorded the ‘Basis of discovery’ as ‘immigrant screening’, the time from x-ray to 
notification was between three to six months, and the case was pulmonary TB. 
 93 
- Not diagnosed by IHS: for active TB cases, i.e. those notified within 6 months of IHS 
screening and without a clear referral pathway or missing notes, were classified as 
‘not diagnosed by IHS’.  
- Cases who did were diagnosed >6 months after their IHS screening were defined as 
‘not diagnosed by IHS’.  
TB cases diagnosed and not diagnosed by screening were discussed in terms of site of TB, x-
ray abnormalities, timeliness of x-rays in relation to IHS submission, and sputum results. To 
understand how INZ screening would need to change to identify cases not diagnosed by 
screening I calculated the proportion of cases by TB status at the time of screening. 
Where available, x-ray films for TB cases were interpreted by an experienced consultant 
radiologist. This interpretation was done without any knowledge of case outcome or previous 
x-ray reports. Results were compared with the reports provided to INZ to assess inter-
observer agreement.  
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Chapter 9: Audit of migration screening records – results  
Introduction 
This study is an audit of the immigration screening records of a sample of foreign-born TB 
cases. Effectiveness and gaps in the immigration screening process were evaluated for TB 
cases who underwent prior screening.  
Derivation of study sample  
During the study period 899 cases of TB were notified to ESR (Figure 5). Those born in New 
Zealand accounted for 165 (18%) notifications. An immigration medical was not available 
for review, because it was not performed in the study period in 391 (44%) notifications, or 
not performed at all in 33 (4%). The arrival date was blank in 74 (8%), notifications and 
records were incomplete in 1 (0.1%) notification. Therefore, detailed records were reviewed 
on 235/899 (26%) cases who had a TB notification and an immigration medical during the 
study period. One hundred and twenty (13%) had an immigration medical assessment 
followed by TB notification during the study period and were included in the study. 
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Figure 5. Derivation of study sample – audit of migration screening records. TB=tuberculosis 
 
Characteristics of tuberculosis cases  
Males accounted for 61/120 (51%) TB notifications (Table 22). Those aged 20-39 constituted 
92/120 (77%) cases, with a further 13/120 (11%) in those 40-64 years old (Figure 6). The 
most frequent visa categories were work visas, with 51/120 (43%) cases, and residence visas 
through the family reunification category with 29/120 (24%) cases. Migrants born in Asia 
accounted for 112/120 (95%) cases, with 77% of all cases from three countries: India, 
Philippines and China. India alone counted for 56/120 (47%) notifications in this study. 
There were no cases from Europe, North America, Latin America and Caribbean, or North 
Africa and Middle East. Screening was performed in New Zealand in 80/120 (67%) cases and 
the remainder performed offshore.   
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Table 22. Characteristics of 120 tuberculosis cases notified following Immigration Health Screening. 
 Number Percent 
Sex 
  
  Female 59 49.2 
  Male 61 50.8    
Age at time of Immigration Health Screening 
  
  <20 12 10.0 
  20-39 92 76.7 
  40-64 13 10.8 
  ³65 3 2.5    
Visa Category  
  
  Residence - Family 29 24.2 
  Refugee 4 3.3 
  Residence - Business / Skilled 2 1.7 
  Student 21 17.5 
  Visitor 13 10.8 
  Work / Skills 51 42.5    
Birth Country Region  
  
  South and Central Asia 61 50.8 
  South East Asia 37 30.8 
  North East Asia 14 11.7 
  Sub-Saharan Africa 3 2.5 
  Pacific 5 4.2    
Clinic where Immigration Health Screening performed  
  
  Off-shore 40 33.3 
  Domestic 80 66.7    




Figure 6. Age distribution of tuberculosis cases at time of Immigration Health Screening. 
 
Disease characteristics 
Based on notification data, 116/120 (97%) cases were in new cases as opposed to relapse or 
reactivation (Table 23). Past TB treatment was disclosed by seven people during their IHS, 
three of whom were classified as having a relapse or reactivation, with four classified as new 
cases. One person was classified as a relapse / reactivation but did not declare past TB 
treatment. Past contact with a TB case was declared in 17/120 (14%) cases; usually in 
childhood or other remote exposures. Laboratory confirmation was recorded for 108/120 
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Exclusively pulmonary TB occurred in 64/120 cases (53%), while 45/120 (38%) were 
exclusively extrapulmonary (Table 23). Both pulmonary and extrapulmonary TB occurred in 
11 (9%) cases.  
In 75 patients with pulmonary TB, 13/75 (17%) had a cavity documented on the ESR 
notification, 24/75 (32%) did not have cavitation, and the remaining 38/75 (51%) were either 
unknown or the data were missing.  
In 56 cases of extrapulmonary TB, there were 66 sites of disease (Table 24). The three most 
frequent sites were lymph nodes, 36 (55%) cases; skin and soft tissue, 7 (11%) cases; and 
pleural, 6 (9%) cases. 
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  Tuberculosis disease - new case 116 96.7 
  Tuberculosis disease - relapse or reactivation* 4 3.3 
   
Past tuberculosis treatment 
  
  No 113 94.2 
  Yes 7 5.8 
   
Contact with a tuberculosis case 
  
  No 79 65.8 
  Unknown 24 20.0 
  Yes 17 14.2 
   
Laboratory confirmed disease   
  No 10 8.3 
  Unknown 2 1.7 
  Yes 108 90.0 
   
Disease site   
  
  Pulmonary 64 53.3 
  Extrapulmonary 45 37.5 
  Pulmonary and Extrapulmonary 11 9.2 
   
Total 120 100.0 
* Reactivation defined as per New Zealand Communicable Disease Control Manual, and does not 




Table 24. Site of extrapulmonary tuberculosis in 56 cases diagnosed following Immigration Health 
Screening. 
Extrapulmonary tuberculosis site  Number  Percent 
  Lymph Node 36 54.5 
  Other extrapulmonary site  2 3.0 
  Pleural 6 9.1 
  Abdominal 5 7.6 
  Soft tissue and skin 7 10.6 
  Miliary 3 4.5 
  Ocular 3 4.5 
  Genitourinary 0 0 
  Central nervous system 2 3.0 
  Bone and joint 2 3.0 
Individuals may have more than one site of disease.  
 
Other medical conditions 
Diabetes was recorded as a specific diagnosis in one case. Another case had an abnormality 
of the endocrine system, detailed as ‘metabolic syndrome and diabetes mellitus’. Three 
further cases (five in total, 4%) had an abnormal HbA1c test, diagnostic of diabetes, although 
the IHS record did not include the actual value. There were two cases with an abnormal 
creatinine, again without comment on the value. There were no cases of HIV, hepatitis B or 
hepatitis C in the cohort. Syphilis serology was reactive in one individual.  
Respiratory abnormalities were noted in four patients, with free text comments specifying 
these were all related to x-ray changes or a history of past TB, which are captured elsewhere 
in the IHS medical. Other system abnormalities, such as musculoskeletal, cardiac and 
urological systems were only documented in one individual each. No cases of cancer were 
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present. The skin and lymph node field contained five abnormalities, but these all related to 
skin changes, with no lymph node abnormalities. 
Time from screening to notification 
The time from IHS submission to TB diagnosis is shown in figure 7. Within three months of 
submission, 38 (32%) cases were notified, and 59 (49%) within six months. The longest 
period from screening to notification was 31 months.   
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Tuberculosis diagnosed by immigration health screening 
Of 120 cases, 42 (35%) were diagnosed by the screening process, 4 (3%) were likely to have 
been and 74 (62%) were not diagnosed by screening (Table 25).  
In cases diagnosed by screening, 36/42 (86%) were pulmonary TB and 6/42 (14%) were 
extrapulmonary TB. There were no cases of mixed pulmonary and extrapulmonary TB 
diagnosed by screening. In cases likely diagnosed by screening, 4/4 (100%) were pulmonary 
TB.  
X-ray abnormalities were present in 35/36 (97%) cases of pulmonary TB that were diagnosed 
by screening, in 3/4 (75%) pulmonary cases likely diagnosed by screening, and in 6/6 (100%) 
extrapulmonary cases diagnosed by screening. The extrapulmonary TB cases diagnosed by 
screening all had an intrathoracic mass that was visible on x-ray.  
In cases not diagnosed by screening, 24/74 (32%) were pulmonary TB, 39/74 (53%) were 
extrapulmonary TB and 11/74 (15%) were mixed pulmonary and extrapulmonary TB. 
Table 25. Tuberculosis diagnosis made by immigration screening and disease site. 
 
Diagnosed by screening 
Disease Site Yes Likely No Total 
Pulmonary  36 4 24 64 
Extrapulmonary  6 0 39 45 
Pulmonary and extrapulmonary  0 0 11 11 
Total 42 4 74 120 
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Likely status at the time of immigration screening and x-ray findings 
The likely status at the time of screening was active TB for 59/120 cases (49%), early TB in 
five cases (4%), inactive TB in three cases (3%), LTBI in 50 cases (42%), and possibly 
uninfected for three cases (3%) (Figure 8).  
 
Figure 8. Likely tuberculosis status at the time of immigration screening. 
 
X-ray reports were available for review in 111/120 (93%) cases. Reports were missing in four 
cases of active TB, four cases of LTBI, and one case possibly uninfected at the time of 
screening.  
Active TB Early TB Inactive TB
Probable LTBI Possibly uninfected
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X-ray features for cases of active TB are shown in table 26. ‘Evidence of TB’ (a yes / no 
question reported by the radiologist) was present in 31/55 (56%) cases of active TB. A range 
of other x-ray findings were seen at various frequencies.  
Scarring or fibrosis was seen in 3/3 (100%) cases of inactive TB reactivation, consistent with 
the study definition of this category of TB. In these three cases, there were no other x-ray 
abnormalities found. The finding of scarring or fibrosis alone is not specific for inactive TB - 
in 21 cases of active TB, five cases also had scarring and fibrosis with no other x-ray 
abnormality.  
The x-ray abnormalities seen in cases of early TB were patchy lesion in 3/5 (60%) cases, 
infiltrate in 4/5 (80%) cases and nodules in 3/5 (60%) cases.  
There were no abnormal x-ray features in 46 cases of LTBI reactivation and in two cases who 
were likely infected in New Zealand, consistent with study definitions.  
X-rays were performed within one month of IHS application (including cases where only an 
x-ray, and no medical examination was required) in 78/120 (65%) cases, and between one to 
three months in 10 (8%) cases. X-rays performed between three months to one year made up 
18/120 (15%) cases. Five (5%) x-rays were performed more than a year before IHS 
submission.  No x-ray was performed (or available for review) in 9/120 (8%) of TB cases.  
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Table 26. X-ray findings in 55 cases of active tuberculosis at the time of screening, where an x-ray is 
available for review. 
X-ray finding Number Percent  
   
Evidence of TB 31 56.3 
Cavity 1 1.8 
Consolidation 3 5.5 
Patchy lesion 12 21.8 
Infiltrate 5 9.1 
Nodules 15 27.3 
Retraction / volume loss 14 25.5 
Scarring / Fibrosis 20 36.4 
Bronchiectatic change 2 3.6 
Cystic change 2 3.6 
Paratracheal / hilar mass 9 16.4 
Pleural effusion 3 5.5 
Calcification (opacity or granuloma) 4 7.3 
Other mass / opacity 2 3.6 
More than one finding may be present per case. TB= tuberculosis  
 
Diagnosis by immigration screening and likely status of tuberculosis 
Table 27 shows the likely condition at the time of screening, and whether these cases were 
diagnosed by the immigration screening process. Active TB was diagnosed by screening in 
42/59 (71%) cases and was likely diagnosed by screening in 4/59 (7%) cases. Active TB was 
not diagnosed by screening in 13/59 (22%) cases. By definition, none of the other categories 
of TB were diagnosed by screening.  
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Table 27. Status of tuberculosis at the time of screening and diagnosis by immigration screening. 
 
Diagnosed by screening 
Status at time of screening Yes Likely No Total 
Active TB 42 4 13 59 
Early TB  0 0 5 5 
Inactive TB  0 0 3 3 
LTBI 0 0 50 50 
Possibly uninfected 0 0 3 3 
Total 42 4 74 120 
TB= tuberculosis. LTBI= latent tuberculosis infection 
In 59 cases of active TB, pulmonary TB (including cases with both pulmonary and 
extrapulmonary TB) was diagnosed by screening in 36/46 (78%) cases, likely diagnosed in 
4/46 (9%) cases and not diagnosed in 6/46 (13%) cases (Table 28).  
Exclusively extrapulmonary, active TB was diagnosed by screening in 6/13 (46%) cases. 
Table 28. Site of tuberculosis and diagnosis by immigration screening for 59 cases of active 
tuberculosis. 
 Diagnosed by screening 
Site of disease  Yes Likely No Total 
Pulmonary  36 4 6 46 
Extrapulmonary  6 0 7 13 
Total 42 4 13 59 
Pulmonary includes cases of mixed pulmonary and extrapulmonary tuberculosis 
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Tuberculosis not diagnosed by immigration screening 
Tuberculosis cases not diagnosed by immigration screening include cases of active TB 
(pulmonary and extrapulmonary), early and inactive TB, LTBI and those possibly uninfected 
at the time of screening.  
Active tuberculosis 
There were thirteen cases of active TB not diagnosed by immigration screening. Six were 
pulmonary and seven were extra pulmonary disease. In six cases of active, pulmonary TB, 
there was no documentation that diagnosis was made by immigration screening. All had a 
basis of diagnosis as ‘attended practitioner’ in notification data. All had immigration 
screening performed in New Zealand.  
In these six cases, 3 (50%) had no x-ray available for review. This may be because an x-ray 
was not performed, documentation was missing, or an x-ray may have been performed 
outside of the study period, and thus not available to the researchers. In the case of the latter, 
based on the timing of IHS for these cases, x-rays would have to be at least 9-14 months old. 
In 2/6 (66%) cases, an old x-ray was submitted with the IHS. One x-ray was between 3-12 
months old, and one was more than 12 months old. In one case, an x-ray with a one month 




Early and inactive TB not diagnosed by immigration screening 
Eight cases met the definition for early or inactive TB. These were cases with x-ray 
abnormalities who were diagnosed >6 months after immigration screening.  
An x-ray was performed within one month of the medical submission in 5/8 (63%) cases, 
between 1-3 months prior to submission in 1/8 (13%) cases, between 3-12 months in 1/8 
(13%) cases, and >12 months in 1/8 (13%) (Table 29).  
Sputum was performed at the time of screening, and was negative for 5/5 (100%) cases of 
early TB and for 1/3 (33%) cases of inactive TB. No sputum testing was performed in 2/3 
(66%) cases of inactive TB. Medical examinations were performed in New Zealand in 3/8 
(38%) cases, with 5/8 performed in an off-shore clinic (63%). Extrapulmonary TB was 
diagnosed in 2/5 (40%) cases of early TB, and 2/3 (66%) cases of inactive TB.  
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Clinic site Site of TB 
Early TB 
Case 
    
1 3-12 month Negative New Zealand Pulmonary 
2 < 1month Negative Off-shore Extrapulmonary 
3 < 1month Negative Off-shore Pulmonary 
4 < 1month Negative Off-shore Pulmonary 
4 > 1 year Negative Off-shore Extrapulmonary 
     
Inactive TB  
Case 
    
1 1-3 month Not done New Zealand Extrapulmonary 
2 < 1month Negative Off-shore Extrapulmonary 
3 < 1month Not done  New Zealand  Pulmonary 





Latent tuberculosis infection and likely uninfected at time of screening 
There were 50 cases of likely LTBI, and three cases likely uninfected at the time of 
screening. By definition, these cases were diagnosed more than six months after screening, 




Blind x-ray interpretation for available x-rays was performed to assess inter-observer 
agreement. Out of 120 notifications, 111 x-ray reports were available in IHS records. There 
were 103 x-ray films available for review by a radiologist. Three x-rays that did not have an 
IHS report had an available film for review, meaning that in total 100/120 (83%) of x-ray 
films and IHS reports were able to be compared.  
X-ray interpretation for IHS reports, and interpretation by a second radiologist for any x-ray 
abnormality are shown in table 30. Overall, agreement between the two is 81%, with a kappa 
score of 0.62.  
Table 30. Agreement between immigration screening x-ray and blind reading by second radiologist.  
Immigration Health  
Screening x-ray 
Second radiologist 
Abnormal Normal Total 
Abnormal 40 10 50 
Normal 9 41 50 
    
Total 49 51 100 
Abnormal refers to the presence of any abnormality 
Cases not diagnosed by screening were compared where x-ray reports and films were 
available (Table 31). In 2/6 cases of active TB not diagnosed by IHS, the IHS report was 
normal and the second radiologist considered the x-ray abnormal. In 6/42 cases of LTBI and 
1/1 cases of ‘possibly not infected at the time of screening’, the IHS report was normal and 
the second radiologist considered the x-ray abnormal. 
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Table 31. Agreement by likely status of tuberculosis between immigration screening x-ray and blind 
reading by second radiologist in cases not diagnosed by screening 
 
 Second Radiologist  
Category and IHS report Normal Abnormal Total 
Active TB  
 
 
  Normal  4 2 6 
  Abnormal 1 1 2 
Early TB  
 
 
  Normal  0 0 0 
  Abnormal 0 5 5 
Inactive TB  
 
 
  Normal  0 0 0 




  Normal  36 6 42 
  Abnormal 2 0 2 
Not infected    
  Normal  0 1 1 
  Abnormal 0 0 0 
Abnormal refers to the presence of any abnormality 
 
Summary 
Screening detected (or was likely to have detected) 46/120 (38%) cases of TB.  
Of the 59 cases of likely active TB at screening, 46/59 (78%) cases were diagnosed, or likely 
diagnosed by screening. Only a further six cases of pulmonary TB were not identified but 
could possibly have been (10% of all active TB cases). The remaining seven cases of active 
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TB not detected by screening were extrapulmonary TB which is not expected to be detected 
by screening. Of cases not diagnosed by screening, 50/74 (68%) were reactivations of LTBI.  
Further scope to improve detection of active pulmonary TB, and new strategies such as LTBI 
screening is discussed in the following chapters.  
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Chapter 10: Audit of migration screening records - discussion 
This study reviewed the immigration health screening records of 120 cases of TB to evaluate 
whether TB was diagnosed at screening, and if not, whether it could have been. To my 
knowledge this is the first evaluation of New Zealand’s TB screening programme that has 
linked screening experience to clinical outcomes.  
Screening likely detected TB in just over one third of cases in the audit. The remainder of 
cases were not detected by screening. The majority of these could not be detected through 
improvements to radiological screening because they were instances of reactivation of LTBI, 
or less commonly, cases of extrapulmonary TB, neither of which can be detected by 
radiological screening. This is despite the very short period of follow up for cases included in 
the study which would tend to favour the inclusion of active TB at the time of screening over 
cases of reactivation of LTBI. The proportions of types of TB in this study should be 
interpreted with caution in light of this likely bias and the small number of cases.  
The purpose of screening is to detect prevalent, pulmonary TB. In this study, 87% of cases of 
active, pulmonary TB were detected, or were likely detected, by screening. The majority of 
these had one or more x-ray abnormalities. Active, pulmonary TB was likely not diagnosed 
by immigration screening in six cases. An old x-ray (reported more than three months prior to 
IHS) was submitted in two cases, and no x-ray was available for review in a further three 
cases (either x-ray not performed, performed prior to the electronic record commencement, or 
missing records). If performed prior to electronic record commencement, based on the timing 
of IHS, this would mean x-rays were at least 9-14 months old. Immigration New Zealand 
allows an old x-ray to be submitted with the medical examination, provided that it is dated 
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within three years of the medical examination and resulted in an acceptable standard of 
health. X-ray abnormalities are the main indicator for further investigation of possible active, 
pulmonary TB; the submission of old x-rays in cases of ‘missed’ active, pulmonary TB 
suggests this x-ray allowance is a possible gap in the screening process. This finding is based 
on a small number of cases only, and there is no analysis of overall volumes of migrants 
screened with old x-rays and their outcomes. A larger study of IHS and x-ray results for TB 
and non-TB cases would be required to analyse the significance of old x-ray submission and 
TB diagnosis.  
The majority of cases of TB not detected by screening in this audit were due to reactivation 
of LTBI. Due to the short follow up time in this study, the true proportion of cases caused by 
LTBI reactivation are unknown. X-ray screening detects prevalent TB but not LTBI that 
could reactivate in the future. Therefore, in countries with well-established and efficacious 
pre-arrival screening programmes, a significant proportion of TB in foreign-born persons is 
notified years after migration. In the United States (37) and New Zealand (2), approximately 
80 percent of people with TB notifications arrived more than one year before diagnosis. In 
the United Kingdom, 80 percent arrived more than two years before diagnosis (39), and in 
Australia, just over a half of people with TB notifications had arrived more than four years 
before diagnosis (7). These cases are most likely due to reactivation of pre-existing LTBI, 
although newly acquired infection (either in the new host country, or after travel to a high-
risk country) is also possible (132). Only a small number of cases in this study were likely 
infected in New Zealand.  
Almost half of cases in this study had extrapulmonary TB, the majority of these with TB 
lymphadenitis. This is a similar proportion to that seen in all extrapulmonary cases in New 
Zealand and the United Kingdom (2,39). Extrapulmonary disease is associated with 
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significant delays and multiple presentations before diagnosis (133). The majority of 
extrapulmonary TB in the audit presented more than six months after screening, and was not 
detected by screening. This is to be expected as screening is not designed to detect 
extrapulmonary TB. A small number of extrapulmonary TB cases with intrathoracic mass or 
lymphadenopathy on x-ray were detected by screening.  
X-ray features at the time of screening were variable for cases of active TB. ‘Evidence of TB’ 
(a mandatory question in the x-ray report) was positive in just over half of cases of active TB. 
This question is not often answered correctly – sometimes an x-ray report would clearly 
indicate TB, yet the ‘evidence of TB’ field is negative. X-ray changes are not specific or 
sensitive for active TB, past TB or non-TB illness, and a review of radiology reports in this 
study also found this. Scarring and fibrosis was reported in all cases of inactive TB 
reactivation, which was defined in the study based on this criterion. Scarring and fibrosis is 
often suggestive of old, or inactive TB, but was also exclusively seen in a small number of 
cases of active TB at screening. This emphasises the importance of following up abnormal x-
ray findings with sputum analysis when TB is suspected.  
There was good inter-observer agreement between x-rays as reported to INZ, and the 
interpretation of a second radiologist performing blind readings. The kappa score of 0.61 
indicates ‘good agreement’ and is consistent with other studies of x-ray interpretation for TB 
(134). Discrepancies were noted between radiologists in a small number of cases of TB not 
detected by screening, in that the radiologist reporting to INZ interpreted an x-ray as normal, 
and the radiologist performing a blind reading interpreted the x-ray as abnormal. X-ray 
interpretation is subjective, but this does raise the possibility that a minority of TB cases were 
not detected due to x-ray misinterpretation.  
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Early and inactive TB was seen in small numbers in this study. By definition, all had x-ray 
abnormalities, and microbiological tests were either negative or not performed. The diagnosis 
of old or inactive TB usually requires x-ray stability over time, and this information is usually 
not available at the time of immigration screening, hence the importance of sputum analysis 
to make a definitive diagnosis of TB in cases with x-ray changes. Migrants with abnormal x-
rays and normal sputum investigation are at higher risk of a later diagnosis of TB (44,91). All 
of the five cases of early TB in this study were appropriately investigated at the time of 
screening with sputum culture. One out of three cases of inactive TB had sputum analysis. 
Half of the cases (combined inactive and early TB) were pulmonary TB, and half 
extrapulmonary TB. Pulmonary cases likely progressed from a low burden of infection not 
detected by initial sputum examination. In Australia, Canada and United States, migrants 
with possible early or inactive TB have scheduled follow-up in an effort to detect the 
development of overt disease (Table 3). There is no formal process for this follow up in New 
Zealand. Given the small numbers of cases in this study, no meaningful conclusion can be 
drawn regarding follow up or repeat examination of migrants with abnormal chest x-rays and 
normal microbiological analysis. The relevance of x-ray changes in the extrapulmonary cases 
is also questionable, as these cases did not have pulmonary disease progression. The 
implications for screening are unclear for this group of migrants.  
The definitions of TB created for this study appear to be reliable, with cases being detected, 
or not detected by screening as expected. Those with active, pulmonary disease were mostly 
detected by screening, and those that were not had identifiable reasons for this (such as 
missing or old x-rays). The created definitions can be applied retrospectively based on ESR 
and INZ records, and therefore can be used for future audit of immigration screening.  
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Most TB cases in the audit were of working age, similar to that seen in the IDI cohort study 
and representative of permanent and long-term migrants to New Zealand (14). Visitors 
comprised a surprising 10% of cases, although it is important to note that only long-term 
visitors require medical screening and are thus included in this group. Long term visitors 
would be expected to have a higher risk of being diagnosed with TB whilst in New Zealand, 
compared with short term visitors who do not require medical screening. Two thirds of cases 
had their screening performed in New Zealand, as opposed to overseas. This is expected in an 
audit of TB cases, where positive screening overseas would result in a visa application being 
declined and the individual not migrating to New Zealand.  
The majority of TB cases were described as new cases in notification data. In a small number 
of cases there was disagreement between IHS disclosures of past TB treatment and 
notification diagnosis of relapse or reactivation. This could suggest notification data 
collection errors or deliberate non-disclosure at immigration screening, due to a fear of past 
TB negatively impacting on immigration decisions.  
The history, examination and laboratory results fields of the immigration medical report 
contributed little to the audit of migrants with TB. Systems abnormalities were found in a 
very low number of those subsequently diagnosed with TB. Respiratory examination 
abnormalities were apparently noted a small number of cases, however this appears to be due 
to incorrect data entry by panel physicians as the abnormalities refer to past history of TB or 
x-ray changes which are documented elsewhere in the IHS. The respiratory examination does 
not contribute significantly to TB diagnosis in general, so the lack of abnormalities seen in 
this audit is not surprising. It is possible that those with TB lymphadenitis may be diagnosed 
by physical examination, however this did not occur in any cases in this study. 
Immunosuppression is a risk factor for TB but was not seen in the majority of cases. Nor 
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were other relevant, chronic medical conditions. This likely reflects the ‘healthy migrant’ 
effect - those of working age and in good health migrating for economic purposes - in this 
study. The lack of contribution of history and examination findings mean that future audits 
could be performed more simply without this information and using the definitions of TB 
status as described above. 
This study includes a small number of TB cases notified in a three-year period in keeping 
with the availability of INZ electronic records. A limitation is that the short follow up period 
biases towards inclusion of active TB. The contribution of reactivation of LTBI in screened 
migrants is likely underestimated due to the short time frame of the study. TB in migrants is 
mostly caused by reactivation of LTBI, rather than active, prevalent disease at migration (33). 
A repeat audit with longer follow up time would likely show a higher proportion of 
notifications distant from IHS submission, reflecting the natural timeline of notifications in 
migrants to low-TB incidence countries.  
The audit included a small number of TB cases, with low numbers of inactive and early TB 
and therefore definitive conclusions and recommendations relating to ongoing surveillance in 
these groups cannot be made.  
Definitions of TB status are not well described in the general, or migrant-specific literature. I 
have attempted to define category of TB present at the time of screening, based on time from 
screening to diagnosis and x-ray features, and acknowledge the arbitrary time frames and 
overlap in x-ray features present in these categories. As described above, definitions did 
perform as expected. Inactive and early TB are defined based on subjective radiological 
findings, and with limited case numbers the distinction is not well validated in this study. A 
small number of cases of LTBI in the study did not have an available x-ray, or had 
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disagreement between radiologist interpretation in those reporting for INZ and the second 
reading in the audit. These cases may have been classified as a different type of TB based on 
x-ray abnormalities or alternative interpretation. Local infection was based on being a part of 
an outbreak, so it is plausible that these cases were the index case and not truly infected 
locally, however I did not have available information to make this distinction. Application of 
these definitions over a larger group would give more certainty to their validity. 
The audit is a case study of TB notifications, and thus lacks comparison with screened 
migrants who did not develop TB. Overall numbers of screening examinations are not 
available. Therefore, the findings of this study cannot be generalised to the wider group of 
screened migrants, and analysis of screening efficacy cannot be made. Nevertheless, this 
study has evaluated cases of TB that developed after screening and has identified some 
potential gaps in New Zealand’s TB screening programme.  
The implications of this study and recommendations for further research are discussed with 
reference to the preceding IDI cohort study in Chapter 11.  
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Chapter 11: Conclusions and recommendations 
Introduction 
Globally tuberculosis is the leading cause of mortality from a single infectious disease, with 
over 10 million new cases and over one million deaths annually (1). The burden of TB is 
highest in low and low-middle income countries. New Zealand has a low incidence of 
tuberculosis that has not changed in the last nine years (2). Migration is the main driver of TB 
in low-incidence countries (33), including New Zealand where 79% of cases are in foreign-
born people. As a signatory to the United Nations Sustainable Development Goals, New 
Zealand has committed to eliminate TB. To do this, New Zealand needs to further reduce its 
TB incidence by targeting high-risk groups, such as migrants. Specific risk factors for TB in 
migrants to New Zealand are not well documented, and this country’s TB screening 
programme has never been formally audited. The New Home study was designed to provide 
information to reduce the burden of TB in migrants to New Zealand and progress this country 
towards TB elimination.  
Main findings  
Region of origin and WHO incidence rate were strongly associated with TB risk in New 
Zealand. The incidence of TB in New Zealand is highest in migrants from South-Central and 
South-East Asia. When countries are grouped according to their WHO incidence bands, New 
Zealand incidence increases proportionately to WHO incidence up to a WHO incidence of 
150-349 per 100,000. At the higher WHO incidence band of ³350 per 100,000, New Zealand 
incidence decreases. Overseas data show similar trends with in-country incidence 
 121 
proportional to WHO incidence (44,83). Those migrating from countries with a WHO 
incidence of <40 per 100,000 have a very low incidence of TB in New Zealand.  
At a country level, two thirds of cases were seen in migrants from three countries – India, 
Philippines, and China. This relates to both high migration from these countries, and the 
incidence of TB in the country of origin. In almost all cases, TB incidence in New Zealand is 
proportionate, but lower than TB incidence in the country of origin. The trend of incidence 
increasing proportionately to that of incidence in the country of origin is seen in other 
countries (44,135,136). The lower New Zealand incidence may reflect off-shore TB cases 
being ‘screened out’ and therefore not migrating, or the ‘healthy migrant effect’ where people 
are migrating for work opportunities, often being relatively healthy and from higher socio-
economic backgrounds. 
Visa category was not associated with TB risk, and age <14 years was associated with lower 
TB risk in this study.  
Screening likely detected TB in one third of cases in the audit. Most of the cases of 
pulmonary, active TB were diagnosed by screening. The majority of cases were not detected 
by screening, most of these due to reactivation of LTBI. The proportion of LTBI in the audit 
of immigration screening study was very likely to be lower than the true proportion of 
reactivation of LBTI in migrants, because the short timeframe of the audit biased results 
towards active TB notifications. International data suggests that a significant portion of TB in 
migrants in low incidence countries develops from LTBI reactivation (33).  
A small number of cases of active, pulmonary TB were likely not detected by screening in 
the audit. The majority of these cases did not have an x-ray available to review, or submitted 
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an older x-ray taken more than three months prior to their immigration screening. In a small 
number of cases not detected by screening, there was disagreement between x-ray reports 
provided to INZ and those from a second, blind reading, raising the possibility that 
interpretation error may have led to a missed diagnosis.  
Extrapulmonary TB was seen in approximately half of TB cases in both the IDI cohort and 
the audit. This is consistent with other New Zealand and international data (2,39).  
Recommendations and future research  
1)  To further reduce TB incidence in New Zealand, new initiatives are required. These 
should focus on migrants because of the known higher incidence of TB and because 
of the inequities noted in this report.  
2) Further analysis of time to diagnosis data from the IDI dataset could give additional 
information on the likely proportion of TB cases in New Zealand to arise from 
reactivation of LTBI. New Zealand and overseas data suggest that a large proportion 
of TB in migrants is LTBI reactivation (2,37,39), and the audit of immigration 
screening shows a high proportion of LTBI reactivation in a short time frame. These 
cases are potentially preventable and further recommendations for LTBI screening are 
discussed below.  
3) Further study in the IDI could assess the impact of socioeconomic status, 
overcrowding, employment, primary health care registration or other health 
conditions on TB risk in migrants. The impact of travel back home to a high-
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incidence country after migration could influence clinical protocols around LTBI 
screening and the timing of LTBI treatment in these migrants.  
4) TB notifications should be included in the IDI and updated on a regular basis. This 
would allow further study on TB risk and study over a longer timeframe. 
5) There is potentially scope for rationalisation of screening of people from low 
prevalence countries. This study showed that migrants from Europe, North America, 
and Latin America and Caribbean contributed only a tiny portion of TB cases 
(maximum 2%) yet made up just under half of all migrants. Similarly, low numbers of 
TB cases and high migration is from countries with a WHO incidence of <40 per 
100,000. However cases identified in off shore screening would not have contributed 
to the cases in this study. A study of off-shore screening yield in migrants to New 
Zealand should be undertaken; if this data is available to INZ, then a reduction in the 
requirement for screening people from low prevalence countries could be possible.   
A Canadian study found very low incidence of TB in migrants from similar regions, 
and calls for universal screening of all migrants to be abandoned in order to focus on 
screening those at increased risk (83). 
6) A clinical evaluation of immigration screening should be performed at regular 
intervals by linking TB notification and IHS data. Evidence of effectiveness and 
quality assurance are important aspects of any screening programme (137). The case 
definitions developed in this study performed well, particularly that of active TB at 
screening, which was detected mostly by screening as expected, and when not 
detected had plausible reasons for this. Applying these definitions across a larger 
dataset with longer follow up would provide more accurate and valid estimates of the 
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proportions of TB cases identified through IHS screening and their likely clinical 
status at the time of diagnosis.  
7) My results suggest that x-ray screening identifies a high proportion of cases with 
likely active pulmonary TB at the time of their screening. There is the potential to 
slightly increase this proportion by requiring a more recent x-ray to be submitted with 
the IHS. The audit was small but this could improve the identification of a small 
number of active TB cases missed by screening by a maximum of 10%. 
8) A small number of cases were not detected by immigration screening and potentially 
had an incorrect x-ray interpretation. However x-ray interpretation is subjective and 
the overall level of agreement was consistent with that of published reports (134). 
Intermittent review of a subset of x-rays could be incorporated into ongoing quality 
assurance procedures. INZ should stay appraised of development in artificial 
intelligence based x-ray reporting as this is a rapidly progressing area with scope to 
provide more reliable diagnosis than human reading (138).  
9) The audit of TB notifications made after screening had small numbers of inactive and 
early TB, and I am unable to make additional screening recommendations for these 
groups. Migrants with abnormal x-rays and negative microbiological examination for 
TB are at significantly higher risk of a later diagnosis of TB (44,91). Formalised 
follow up of these cases is instituted in other IRHWG countries (Table 3). Prospective 
follow up studies of this group could assist with defining the risk of TB in this 
context, and well as identifying biomarkers for risk of developing TB, and performing 
randomised controlled trials to better define the optimal treatment for this group if TB 
treatment is initiated presumptively.   
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10) LTBI screening of migrants to New Zealand needs to be actively investigated as it is 
likely to be a necessary element of efforts to reduce TB in migrants to New Zealand. 
It is likely that this could be targeted according to an incidence threshold with 
consideration given to exceptions for people from countries were incidence correlates 
poorly with risk in New Zealand. Even a low incidence threshold like >40 per 
100,000 removes the need to screen half the migrant cohort but could potentially 
prevent 96% of TB cases in migrants to New Zealand.  
11) Children do not currently require x-ray screening in New Zealand. Selected migrant 
children are screened for LTBI in Australia and United States (74,75,80). Children are 
not a high risk group for TB in the cohort study, however young children are in 
general at higher risk of reactivation of LTBI (16), and should be included in any 
further research into LTBI screening in New Zealand.  
12) The yield of LTBI screening in New Zealand is unknown and should be estimated 
through a prevalence survey. This will help project the number of migrants who are 
likely to test positive and therefore the need for treatment services if screening is 
implemented. A cost-effectiveness or cost-benefit analysis of screening could then be 
performed and consideration given to the capacity of the health system to screen and 
provide treatment.  
13) Other key considerations in the implementation of a screening programme are around 
screening acceptance, treatment acceptance and treatment completion rates. Screening 
programmes overseas have varying treatment completion rates, but are high in some 
studies (39,106,107). Further investigation of successful programmes would guide 
implementation in New Zealand.  
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14) Consultation with migrant groups to gauge the acceptability of screening and 
treatment would need to be performed prior to any recommendation to incorporate 
LTBI screening into a national programme. As LTBI is non-infectious, compulsory 
treatment would not be ethical and any recommendations made to change screening 
policy would need to emphasise this.  
Conclusion 
Current screening of migrants for TB in New Zealand does what it is designed to do – detect 
active, pulmonary TB before, or at the time of migration. This reduces the importation of 
transmissible TB, however most TB in migrants is caused by the reactivation of LTBI some 
time after migration. Extrapulmonary TB is also seen in high proportions of migrants. 
Screening with chest radiography is not designed to detect LTBI, nor does it detect 
extrapulmonary TB. New strategies are required to reduce the burden of TB in migrants and 
progress towards TB elimination in New Zealand. 
The next approach is to consider targeted LTBI screening and treatment of migrants. Further 
research in the IDI could assess the time frames from arrival to notification and the impact of 
travel back home to a high-incidence country. Outside of the IDI, research into the feasibility, 
acceptability, health system capacity and cost-benefit of structured LTBI testing is required 
before any firm recommendations can be made. If shown to be feasible and acceptable, LTBI 
screening and preventive treatment has the potential to significantly reduce the burden of TB 
in migrants to this country, benefiting them, their families and progressing New Zealand 
towards the elimination of tuberculosis.
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Country and designated region used in both IDI cohort study and audit of migration records.  
 
 
Country / State   Region 
Albania    Europe 
Algeria    North Africa and Middle East 
American Samoa   Pacific 
Andorra    Europe 
Angola    Sub-Saharan Africa 
Antigua and Barbuda   Latin America and Caribbean  
Argentina    Latin America and Caribbean  
Armenia    Europe 
Austria    Europe 
Azerbaijan    Europe 
Bahamas    Latin America and Caribbean  
Bahrain    North Africa and Middle East 
Bangladesh    South-Central Asia 
Barbados    Latin America and Caribbean  
Belarus    Europe 
Belgium    Europe 
Belize     Latin America and Caribbean  
Benin     Sub-Saharan Africa 
Bermuda    Latin America and Caribbean  
Bhutan     South-Central Asia 
Bolivia    Latin America and Caribbean  
Bosnia and Herzegovina  Europe 
Botswana    Sub-Saharan Africa 
Brazil     Latin America and Caribbean  
Brunei Darussalam   South-East Asia 
Bulgaria    Europe 
Burkina Faso    Sub-Saharan Africa 
Burundi    Sub-Saharan Africa 
Cambodia    South-East Asia 
Cameroon    Sub-Saharan Africa 
Canada    North America 
Cape Verde    Sub-Saharan Africa 
Cayman Islands   Latin America and Caribbean  
Chad     Sub-Saharan Africa 
Chile     Latin America and Caribbean  
China     North-East Asia 
Colombia    Latin America and Caribbean  
Comoros    Sub-Saharan Africa 
Congo     Sub-Saharan Africa 
Congo – Democratic Republic of Sub-Saharan Africa 
Costa Rica    Latin America and Caribbean  
Croatia    Europe 
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Cuba     Latin America and Caribbean  
Cyprus     Europe 
Czech Republic   Europe 
Denmark    Europe 
Djibouti    Sub-Saharan Africa 
Dominica    Latin America and Caribbean  
Dominican Republic   Latin America and Caribbean  
East Timor    South-East Asia 
Ecuador    Latin America and Caribbean  
Egypt     North Africa and Middle East 
El Salvador    Latin America and Caribbean  
Equatorial Guinea   Sub-Saharan Africa 
Eritrea     Sub-Saharan Africa 
Estonia    Europe 
Ethiopia    Sub-Saharan Africa 
Faeroe Islands    Europe 
Federated States of Micronesia Pacific 
Fiji     Pacific  
Finland    Europe 
France     Europe 
French Polynesia   Pacific 
Gabon     Sub-Saharan Africa 
Gambia    Sub-Saharan Africa 
Georgia    Europe 
Germany    Europe 
Ghana     Sub-Saharan Africa 
Gibraltar    Europe 
Great Britain    Europe 
Greece     Europe 
Grenada    Latin America and Caribbean  
Guatemala     Latin America and Caribbean  
Guinea     Sub-Saharan Africa 
Guinea-Bissau    Sub-Saharan Africa 
Guyana    Latin America and Caribbean   
Haiti     Latin America and Caribbean  
Honduras    Latin America and Caribbean  
Hong Kong    North-East Asia 
Hungary    Europe 
Iceland    Europe 
India     South-Central Asia 
Indonesia    South-East Asia 
Iran     North Africa and Middle East 
Iraq     North Africa and Middle East 
Ireland     Europe 
Israel     North Africa and Middle East 
Italy      Europe 
Ivory Coast    Sub-Saharan Africa 
Jamaica     Latin America and Caribbean  
Japan      North-East Asia 
Jordan     North Africa and Middle East 
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Kazakhstan    South-Central Asia 
Kenya     Sub-Saharan Africa 
Kiribati    Pacific 
Kosovo – Republic of   Europe 
Kuwait    North Africa and Middle East 
Kyrgyzstan    South-Central Asia 
Laos     South-East Asia 
Latvia     Europe 
Lebanon    North Africa and Middle East 
Lesotho    Sub-Saharan Africa 
Liberia     Sub-Saharan Africa 
Libya     North Africa and Middle East 
Liechtenstein     Europe 
Lithuania     Europe 
Luxembourg    Europe 
Macau     North-East Asia 
Macedonia    Europe 
Madagascar     Sub-Saharan Africa 
Malawi    Sub-Saharan Africa  
Malaysia    South-East Asia 
Maldives    South-Central Asia 
Mali     Sub-Saharan Africa 
Malta     Europe 
Marshall Islands   Pacific 
Mauritania    Sub-Saharan Africa 
Mauritius    Sub-Saharan Africa 
Mexico    North America 
Moldova    Europe 
Monaco    Europe 
Mongolia    South-Central Asia 
Montenegro     Europe 
Morocco    North Africa and Middle East 
Mozambique    Sub-Saharan Africa 
Myanmar    South-East Asia 
Namibia    Sub-Saharan Africa 
Nauru     Pacific 
Nepal     South-Central Asia 
Netherlands    Europe 
Netherlands Antilles   Latin America and Caribbean  
New Caledonia   Pacific 
Nicaragua     Latin America and Caribbean  
Niger     Sub-Saharan Africa 
Nigeria     Sub-Saharan Africa 
North Korea    North-East Asia 
Norway    Europe 
Oman     North Africa and Middle East 
Pakistan    South-Central Asia 
Palau     Pacific 
Palestine    North Africa and Middle East 
Panama    Latin America and Caribbean   
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Papua New Guinea   Pacific 
Paraguay    Latin America and Caribbean  
Peru     Latin America and Caribbean  
Philippines     South-East Asia 
Poland     Europe 
Portugal    Europe 
Puerto Rico    Latin America and Caribbean  
Qatar     North Africa and Middle East 
Romania    Europe 
Russia     Europe 
Rwanda    Sub-Saharan Africa 
Samoa     Pacific 
San Marino    Europe 
Sao Tome and Principe  Sub-Saharan Africa 
Saudi Arabia    North Africa and Middle East 
Senegal    Sub-Saharan Africa 
Serbia     Europe 
Serbia and Montenegro  Europe 
Seychelles     Sub-Saharan Africa 
Sierra Leone    Sub-Saharan Africa 
Singapore    South-East Asia 
Slovakia    Europe 
Slovenia    Europe 
Solomon Islands   Pacific 
South Africa    Sub-Saharan Africa 
South Korea    North-East Asia 
Soviet Union    Europe 
Spain     Europe 
Sri Lanka    South-Central Asia 
St Kitts – Nevis   Latin America and Caribbean  
St Lucia    Latin America and Caribbean  
St Vincent and Grenadines  Latin America and Caribbean  
Sudan     Sub-Saharan Africa 
Surinam    Latin America and Caribbean  
Swaziland    Sub-Saharan Africa 
Sweden    Europe 
Switzerland    Europe 
Syria     North Africa and Middle East 
Taiwan    North-East Asia  
Tajikistan    South-Central Asia 
Tanzania    Sub-Saharan Africa 
Thailand    South-East Asia 
Timor-Leste    South-East Asia 
Togo     Sub-Saharan Africa 
Tonga     Pacific 
Trinidad and Tobago   Latin America and Caribbean  
Tunisia    North Africa and Middle East 
Turkey     Europe 
Turkmenistan    South-Central Asia 
Tuvalu     Pacific 
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Uganda    Sub-Saharan Africa 
Ukraine    Europe 
United Arab Emirates   North Africa and Middle East 
United States of America  North America 
Uruguay    Latin America and Caribbean  
Uzbekistan    South-Central Asia 
Vanuatu    Pacific 
Vatican City    Europe 
Venezuela    Latin America and Caribbean  
Vietnam    South-East Asia 
Yemen     North Africa and Middle East 
Yugoslavia    Europe 
Zambia    Sub-Saharan Africa 
Zimbabwe    Sub-Saharan Africa 
 
 
 
 
